

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07514 A2

- (51) International Patent Classification⁷: A01N (FI). OLOFSSON, Birgitta; University of California at San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0448 (FI). ERIKSSON, Ulf; c/o Ludwig Institute for Cancer Research, Box 240, S-17177 Stockholm (SE).
- (21) International Application Number: PCT/US01/23707
- (22) International Filing Date: 26 July 2001 (26.07.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/220,824 26 July 2000 (26.07.2000) US
- (71) Applicants: LUDWIG INSTITUTE OF CANCER RESEARCH [US/US]; 605 Third Avenue, New York, NY 10158 (US). LICENTIA LTD. [FI/FI]; Erottajankatu 19 B 5, FIN-00130 Helsinki (FI).
- (74) Agent: EVANS, Joseph, D.; Crowell & Moring LLP, Intellectual Property Group, P.O. Box 14300, Washington, DC 20044-4300 (US).
- (81) Designated States (national): AU, CA, CN, JP, KR, NZ.
- (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
- Published:
— without international search report and to be republished upon receipt of that report
- (72) Inventors: JELTSCH, Markku; c/o Licentia Ltd., Erottajankatu 19 B 5, FIN-00130 Helsinki (FI). ALITALO, Kari; c/o Licentia Ltd., Erottajankatu 19 B 5, FIN-00130 Helsinki
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/07514 A2

(54) Title: GLYCOSYLATED VEGF-B AND METHOD FOR INCREASING THE AMOUNT OF SOLUBLE VEGF-B

(57) Abstract: N-glycosylated VEGF-B proteins, nucleic molecule encoding these proteins, pharmaceutical compositions containing them and a method of increasing the amount of a soluble VEGF-B protein. The VEGF-B proteins are useful in stimulating and maintaining angiogenesis.

GLYCOSYLATED VEGF-B AND METHOD FOR
INCREASING THE AMOUNT OF SOLUBLE VEGF-B

BACKGROUND OF THE INVENTION

This invention relates to the discovery that N-glycosylation of VEGF-B causes an increase in soluble proteins.

The two major components of the mammalian vascular system are endothelial cells and smooth muscle cells. The endothelial cells form the lining of the inner surface of all blood vessels and lymphatic vessels in the mammal. The formation of new blood vessels can occur by two different processes, vasculogenesis or angiogenesis (for a review see Risau, W., Nature 386:671-674 (1997)). Vasculogenesis is characterized by the *in situ* differentiation of endothelial cell precursors to mature endothelial cells and association of these cells to form vessels, such as occurs in the formation of the primary vascular plexus in the early embryo. In contrast, angiogenesis, the formation of blood vessels by growth and branching of pre-existing vessels, is important in later embryogenesis and is responsible for most of the blood vessel growth which occurs in the adult. Angiogenesis is a physiologically complex process involving proliferation of endothelial cells, degradation of extracellular matrix, branching of vessels and subsequent cell adhesion events. In the adult, angiogenesis is tightly controlled and limited under normal circumstances to the female reproductive system. However angiogenesis can be switched on in response to tissue damage. Also solid tumors are able to induce angiogenesis in surrounding tissue, thus sustaining tumor growth and facilitating the formation of metastases (Folkman, J., Nature Med. 1:27-31,

(1995)). The molecular mechanisms underlying the complex angiogenic processes are far from being understood.

Angiogenesis is also involved in a number of pathological conditions, where it plays a role or is involved directly in 5 different sequelae of the disease. Some examples include neovascularization associated with various liver diseases, neovascular sequelae of diabetes, neovascular sequelae to hypertension, neovascularization in post-trauma, neovascularization due to head trauma, neovascularization in 10 chronic liver infection (e.g. chronic hepatitis), neovascularization due to heat or cold trauma, dysfunction related to excess of hormone, creation of hemangiomas and restenosis following angioplasty. In arthritis, new capillaries invade the joint and destroy cartilage. In diabetes, new 15 capillaries in the retina invade the vitreous humour, causing bleeding and blindness (Folkman, J. and Shing, Y., J. Biol. Chem. 267:10931-10934 (1992)). The role of angiogenic factors in these and other diseases has not yet been clearly established.

Because of the crucial role of angiogenesis in so many 20 physiological and pathological processes, factors involved in the control of angiogenesis have been intensively investigated. A number of growth factors have been shown to be involved in the regulation of angiogenesis. These include fibroblast growth factors (FGFs), platelet-derived growth factors (PDGFs), 25 transforming growth factor alpha (TGF), and hepatocyte growth factor (HGF). See for example Folkman et al, J. Biol. Chem., 267:10931-10934 (1992) for a review.

It has been suggested that a particular family of endothelial cell-specific growth factors known as the vascular 30 endothelial growth factors (VEGFs) and their corresponding receptors are primarily responsible for stimulation of endothelial cell growth and differentiation, and for certain functions of the differentiated cells. These factors are members

of the PDGF/VEGF family, and appear to act primarily via endothelial receptor tyrosine kinases (RTKs). The PDGF/VEGF family of growth factors belongs to the cystine-knot superfamily of growth factors, which also includes the neurotrophins and transforming growth factor- β .

Eight different proteins have been identified in the PDGF/VEGF family, namely two PDGFs (A and B), VEGF and five members that are closely related to VEGF. The five members closely related to VEGF are: VEGF-B, described in International Patent Application No. WO 96/26736 and in U.S. Patent Nos. 5,840,693 and 5,607,918 by Ludwig Institute for Cancer Research and The University of Helsinki; VEGF-C or VEGF2, described in Joukov et al, EMBO J. 15:290-298 (1996), Lee et al, Proc. Natl. Acad. Sci. USA 93:1988-1992 (1996), and U.S. Patents 5,932,540 and 5,935,540 by Human Genome Sciences, Inc; VEGF-D, described in International Patent Application No. PCT/US97/14696 (WO 98/07832), and Achen et al, Proc. Natl. Acad. Sci. USA 95:548-553 (1998); the placenta growth factor (PlGF), described in Maglione et al, Proc. Natl. Acad. Sci. USA 88:9267-9271 (1991); and VEGF3, described in International Patent Application No. PCT/US95/07283 (WO 96/39421) by Human Genome Sciences, Inc. Each VEGF family member has between 30% and 45% amino acid sequence identity with VEGF in their VEGF homology domain (VHD). This VEGF homology domain contains the eight conserved cysteine residues which form the cystine-knot motif. In their active, physiological state, the proteins are dimers. Functional characteristics of the VEGF family include varying degrees of mitogenicity for endothelial cells and related cell types, induction of vascular permeability and angiogenic and lymphangiogenic properties.

Vascular endothelial growth factor (VEGF) is a homodimeric glycoprotein that has been isolated from several sources. VEGF shows highly specific mitogenic activity for endothelial cells. VEGF has important regulatory functions in the formation of new

blood vessels during embryonic vasculogenesis and in angiogenesis during adult life (Carmeliet et al., Nature, 380: 435-439, (1996); Ferrara et al., Nature, 380: 439-442, (1996); reviewed in Ferrara and Davis-Smyth, Endocrine Rev., 18: 4-25, (1997)).

5 The significance of the role played by VEGF has been demonstrated in studies showing that inactivation of a single VEGF allele results in embryonic lethality due to failed development of the vasculature (Carmeliet et al., Nature, 380: 435-439, (1996); Ferrara et al., Nature, 380: 439-442, (1996)). The isolation and

10 properties of VEGF have been reviewed; see Ferrara et al., J. Cellular Biochem., 47: 211-218, (1991) and Connolly, J. Cellular Biochem., 47: 219-223, (1991).

In addition, VEGF has strong chemoattractant activity towards monocytes, can induce the plasminogen activator and the

15 plasminogen activator inhibitor in endothelial cells, and can also induce microvascular permeability. Because of the latter activity, it is sometimes referred to as vascular permeability factor (VPF). VEGF is also chemotactic for certain hematopoietic cells. Recent literature indicates that VEGF blocks maturation

20 of dendritic cells and thereby reduces the effectiveness of the immune response to tumors (many tumors secrete VEGF) (Gabrilovich et al., Blood 92: 4150-4166, (1998); Gabrilovich et al., Clinical Cancer Research 5: 2963-2970, (1999)).

Vascular endothelial growth factor B (VEGF-B) has similar

25 angiogenic and other properties to those of VEGF, but is distributed and expressed in tissues differently from VEGF. In particular, VEGF-B is very strongly expressed in heart, and only weakly in lung, whereas the reverse is the case for VEGF (Olofsson, B. et al, Proc. Natl. Acad. Sci. USA 93:2576-2581

30 (1996)). RT-PCR assays have demonstrated the presence of VEGF-B mRNA in melanoma, normal skin, and muscle. This suggests that VEGF and VEGF-B, despite the fact that they are co-expressed in many tissues, may have functional differences. A comparison of

the PDGF/VEGF family of growth factors reveals that the 167 amino acid isoform of VEGF-B is the only family member that is completely devoid of any glycosylation. Gene targeting studies have shown that VEGF-B deficiency results in mild cardiac phenotype, and impaired coronary vasculature (Bellomo et al, Circ. Res. 86:E29-35 (2000)).

Human VEGF-B was isolated using a yeast co-hybrid interaction trap screening technique by screening for cellular proteins which might interact with cellular retinoic acid-binding protein type I (CRABP-I). The isolation and characteristics including nucleotide and amino acid sequences for both the human and mouse VEGF-B are described in detail in International Application No. WO 96/26736 and in U.S. Patent Nos. 5,840,693 and 5,607,918 by Ludwig Institute for Cancer Research and The University of Helsinki and in Olofsson et al, Proc. Natl. Acad. Sci. USA 93:2576-2581 (1996). The nucleotide sequence for human VEGF-B is also found at GenBank Accession No. U48801. The entire disclosures of WO 96/26736, US 5,840,693 and US 5,607,918 are incorporated herein by reference. The mouse and human genes for VEGF-B are almost identical, and both span about 4 kb of DNA. The genes are composed of seven exons and their exon-intron organization resembles that of the VEGF and PlGF genes (Grimmond et al, Genome Res. 6:124-131 (1996); Olofsson et al, J. Biol. Chem. 271:19310-19317 (1996); Townson et al, Biochem. Biophys. Res. Commun. 220:922-928 (1996)).

VEGF-C was isolated from conditioned media of the PC-3 prostate adenocarcinoma cell line (CRL1435) by screening for ability of the medium to induce tyrosine phosphorylation of the endothelial cell-specific receptor tyrosine kinase VEGFR-3 (Flt4), using cells transfected to express VEGFR-3. VEGF-C was purified using affinity chromatography with recombinant VEGFR-3, and was cloned from a PC-3 cDNA library. Its isolation and

characteristics are described in detail in Joukov et al., EMBO J., 15: 290-298, (1996).

VEGF-D was isolated from a human breast cDNA library, commercially available from Clontech, by screening with an expressed sequence tag obtained from a human cDNA library designated "Soares Breast 3NbHBst" as a hybridization probe (Achen et al, Proc. Natl. Acad. Sci. USA, 95: 548-553, (1998)). Its isolation and characteristics are described in detail in International Patent Application No. WO98/07832 and in U.S. Patent No. 6,235,713. These documents also describe the isolation of a biologically active fragment of VEGF-D which consists of VEGF-D amino acid residues 93 to 201. The VEGF-D gene is broadly expressed in the adult human, but is certainly not ubiquitously expressed. VEGF-D is strongly expressed in heart, lung and skeletal muscle. Intermediate levels of VEGF-D are expressed in spleen, ovary, small intestine and colon, and a lower expression occurs in kidney, pancreas, thymus, prostate and testis. No VEGF-D mRNA was detected in RNA from brain, placenta, liver or peripheral blood leukocytes.

PlGF was isolated from a term placenta cDNA library. Its isolation and characteristics are described in detail in Maglione et al., Proc. Natl. Acad. Sci. USA, 88: 9267-9271, (1991). Presently its biological function is not well understood.

VEGF3 was isolated from a cDNA library derived from colon tissue. VEGF3 is stated to have about 36% identity and 66% similarity to VEGF. The method of isolation of the gene encoding VEGF3 is unclear and no characterization of the biological activity is disclosed in International Patent Application No. PCT/US95/07283 (WO 96/39421).

Similarity between two proteins is determined by comparing the amino acid sequence and conserved amino acid substitutions of one of the proteins to the sequence of the second protein,

whereas identity is determined without including the conserved amino acid substitutions.

As noted above, the PDGF/VEGF family members act primarily by binding to receptor tyrosine kinases. In general, receptor tyrosine kinases are glycoproteins, which consist of an extracellular domain capable of binding a specific growth factor(s), a transmembrane domain, which is usually an alpha-helical portion of the protein, a juxtamembrane domain, which is where the receptor may be regulated by, e.g., protein phosphorylation, a tyrosine kinase domain, which is the enzymatic component of the receptor and a carboxy-terminal tail, which in many receptors is involved in recognition and binding of the substrates for the tyrosine kinase.

Five endothelial cell-specific receptor tyrosine kinases have been identified, belonging to two distinct subclasses: three vascular endothelial cell growth factor receptors, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt4), and the two receptors of the Tie family, Tie and Tie-2 (Tek). These receptors differ in their specificity and affinity. All of them have the intrinsic tyrosine kinase activity which is necessary for signal transduction.

The only receptor tyrosine kinases known to bind VEGFs are VEGFR-1, VEGFR-2 and VEGFR-3. VEGFR-1 and VEGFR-2 bind VEGF with high affinity, and VEGFR-1 also binds PlGF. VEGF-B binds to VEGFR-1 with high affinity, but not to VEGFR-2 or -3 (Olofsson et al, Proc. Natl. Acad. Sci. USA, 95:11709-11714 (1998)). VEGF-C has been shown to be the ligand for VEGFR-3, and it also activates VEGFR-2 (Joukov et al, The EMBO Journal 15:290-298 (1996)). VEGF-D binds to both VEGFR-2 and VEGFR-3 (Achen et al, Proc. Natl. Acad. Sci. USA 95:548-553 (1998)). A ligand for Tek/Tie-2 has been described in International Patent Application No. PCT/US95/12935 (WO 96/11269) by Regeneron Pharmaceuticals, Inc. The ligand for Tie has not yet been identified.

A novel 130-135 kDa VEGF isoform specific receptor also has been purified and cloned (Soker et al, Cell 92:735-745 (1998)). The VEGF receptor was found to specifically bind the VEGF₁₆₅ isoform via the exon 7 encoded sequence, which shows weak 5 affinity for heparin (Soker et al, Cell 92:735-745 (1998)). Surprisingly, the receptor was shown to be identical to human neuropilin-1 (NP-1), a receptor involved in early stage neuromorphogenesis. PlGF-2 also appears to interact with NP-1 (Migdal et al, J. Biol. Chem. 273:22272-22278 (1998)).

10 VEGFR-1, VEGFR-2 and VEGFR-3 are expressed differently by endothelial cells. Generally, both VEGFR-1 and VEGFR-2 are expressed in blood vessel endothelia (Oelrichs et al, Oncogene 8:11-18 (1992); Kaipainen et al, J. Exp. Med. 178:2077-2088 (1993); Dumont et al, Dev. Dyn. 203:80-92 (1995); Fong et al, 15 Dev. Dyn. 207:1-10 (1996)) and VEGFR-3 is mostly expressed in the lymphatic endothelium of adult tissues (Kaipainen et al, Proc. Natl. Acad. Sci. USA 9:3566-3570 (1995)). VEGFR-3 is also expressed in the blood vasculature surrounding tumors.

Although VEGFR-1 is mainly expressed in endothelial cells 20 during development, it can also be found in hematopoietic precursor cells during early stages of embryogenesis (Fong et al, Nature 376:66-70 (1995)). In adults, monocytes and macrophages also express this receptor (Barleon et al, Blood 87:3336-3343 (1995)). In embryos, VEGFR-1 is expressed by most, if not all, 25 vessels (Breier et al, Dev. Dyn. 204:228-239 (1995); Fong et al, Dev. Dyn. 207:1-10 (1996)).

Since the identification and characterization of VEGF, a number of important findings have focused attention on the activity of angiogenic factors and the elucidation of new 30 factors. The early findings showed that angiogenesis is required for normal development and physiology. Processes such as embryogenesis, wound healing, and corpus luteum formation, all involve angiogenesis and angiogenic factors. During wound

healing, for example, VEGF mRNA levels increase suggesting a direct correlation between the expression of VEGF and the healing process. Also, a defect in VEGF regulation might be associated with wound healing disorders (Frank, S., et al, J. Biol. Chem. 5 2705:12607-12613 (1995)).

Another important finding involves the connection between angiogenesis and tumor development. Both tumor growth and metastasis are angiogenesis-dependent processes (Folkman, J. and Shing, Y., J. Biol. Chem. 267: 10931-10934 (1992)). For example, 10 when tumor cells are introduced into an animal, the expression pattern of VEGF mRNA reveals expression at the highest level in cells at the periphery of necrotic, tumor growth areas. Numerous blood vessels were identified within these areas. The expression of VEGF in these areas suggests that hypoxemia, a state of 15 deficient oxygenation, triggers expression and release of VEGF in the necrotic tumor. The expression of VEGF-B also has been directly correlated with tumor growth (see U.S. Patent No. 5,840,693). VEGF-B expression is especially up regulated in tumor-associated macrophages and also in ovarian epithelial 20 tumors (Sowter et al, Lab Invest. 77:607-14, (1997)). VEGF-B mRNA can be detected in most tumor cell lines investigated, including adenocarcinoma, breast carcinoma, lymphoma, squamous cell carcinoma, melanoma, fibrosarcoma and Schwannoma (Salven et al, Am J Pathol. 153:103-8 (1998)).

25 It has been shown that members of the VEGF/PDGF family produce variant transcripts. VEGF has been shown to display different transcripts because of alternative splicing. The human VEGF gene has five different mRNA species (Neufeld et al, FASEB J. 13:9-22 (1999)), resulting in proteins differing in their 30 molecular mass and biological properties (Carmeliet, P., Nat. Med. 6:389-395 (2000)). The hVEGF-A₁₆₅ isoform is the predominant transcript in most human tissues, giving rise to a polypeptide with affinity to the neuropilin-1 receptor, besides the binding

to VEGFR1 and VEGFR2. The hVEGF₁₂₁ and hVEGF₁₈₉ isoforms are expressed in normal tissues at lower levels. The hVEGF₂₀₆ isoform is mainly expressed in embryonic tissues (Houck et al, Mol Endocrinol. 5:1806-14 (1991)), while hVEGF₁₄₅ can only be found in 5 tumor cell lines (Poltorak et al, J Biol Chem. 272:7151-8 (1997)). Moreover, VEGF is also regulated in an isoform-specific way under pathological conditions. In lung and colon carcinomas, hVEGF₁₆₅ and hVEGF₁₂₁ are up-regulated, whereas hVEGF₁₈₉ is not changed, suggesting an isoform-specific role of VEGF in 10 malignancy (Cheung et al, Hum Pathol. 29:910-4 (1998)). An isoform specific VEGF targeting experiment with murine VEGF-B has shown that mVEGF₁₆₄ and mVEGF₁₈₈ are more important for postnatal growth and maintenance of normal function of cardiovascular system, while mVEGF₁₂₀ initiates and promotes vasculogenesis 15 (Carmeliet et al, Nat Med. 5:495-502 (1999)).

The placenta growth factor (PlGF) has three different isoforms, which are expressed in a tissue and development specific way (Maglione et al, Oncogene 8:925-31 (1993); Cao et al, Biochem Biophys Res Commun. 235:493-8 (1997)).

20 Two isoforms of VEGF-B, generated by alternative splicing of mRNA, have been recognized (Grimmond et al, Genome Res. 6:124-131 (1996); Olofsson et al, J. Biol. Chem. 271:19310-19317 (1996); Townson et al, Biochem. Biophys. Res. Commun. 220:922-928 (1996)). They are a cell associated form of 167 amino acid 25 residues (VEGF-B₁₆₇) and a secreted form of 186 amino acid residues (VEGF-B₁₈₆). The isoforms have an identical N-terminal domain of 115 amino acid residues, excluding the signal sequence. The common N-terminal domain is encoded by exons 1-5. Differential use of the remaining exons 6A, 6B and 7 gives rise 30 to the two splice isoforms. By the use of an alternative splice-acceptor site in exon 6, an insertion of 101 bp introduces a frame-shift and a stop of the coding region of VEGF-B₁₆₇ cDNA. Thus, the two VEGF-B isoforms have differing C-terminal domains.

The different C-terminal domains of the two splice isoforms of VEGF-B affect their biochemical and cell biological properties. The C-terminal domain of VEGF-B₁₆₇ is structurally related to the corresponding region in VEGF, with several 5 conserved cysteine residues and stretches of basic amino acid residues. Thus, this domain is highly hydrophilic and basic and, accordingly, VEGF-B₁₆₇ will remain cell-associated on secretion, unless the producing cells are treated with heparin or high salt concentrations. The cell-associated molecules binding VEGF-B₁₆₇ 10 are likely to be cell surface or pericellular heparin sulfate proteoglycans. It is likely that the cell-association of this isoform occurs via its unique basic C-terminal region.

The C-terminal domain of VEGF-B₁₈₆ has no significant similarity with known amino acid sequences in the databases. The 15 hydrophobic character of the C-terminal domain of VEGF-B₁₈₆ contrasts with the properties of the hydrophilic and basic C-terminal domain of VEGF-B₁₆₇. This is supported by the observation that VEGF-B₁₈₆ does not remain cell-associated on its secretion. Recent evidence indicates that this isoform is 20 proteolytically processed, which regulates the biological properties of the protein (Olofsson et al., Proc. Natl. Acad. Sci. USA, 95:11709-11714 (1998)).

A further difference is found in the glycosylation of the VEGF-B isoforms. VEGF-B₁₆₇ is not glycosylated at all, whereas 25 VEGF-B₁₈₆ is O-glycosylated but not N-glycosylated.

Both isoforms of VEGF-B also form heterodimers with VEGF, consistent with the conservation of the eight cysteine residues involved in inter- and intramolecular disulfide bonding of PDGF-like proteins. Furthermore, co-expression of VEGF-B and VEGF in 30 many tissues suggests that VEGF-B-VEGF heterodimers occur naturally. Heterodimers of VEGF-B₁₆₇-VEGF remain cell-associated. In contrast, heterodimers of VEGF-B₁₈₆ and VEGF are freely secreted from cells in a culture medium. VEGF also forms

heterodimers with PlGF (DiSalvo, et al, J. Biol. Chem. 270:7717-7723 (1995)). The production of heterodimeric complexes between the members of this family of growth factors could provide a basis for a diverse array of angiogenic or regulatory molecules.

- 5 Since the secreted VEGF-B₁₆₇ remains cell-associated, it is intrinsically difficult to obtain significant amounts of soluble VEGF-B₁₆₇. Accordingly, there is a need to develop methods for increasing the amount of soluble VEGF-B₁₆₇.

10 SUMMARY OF THE INVENTION

This invention relates to a N-glycosylated VEGF-B and a method for increasing the amount of soluble VEGF-B proteins.

- In a first aspect, the invention provides a purified and isolated nucleic acid molecule having a polynucleotide sequence
15 selected from the group consisting of SEQ ID NO:1 (sequence encoding VEGF-B₁₆₇), SEQ ID NO:3 (sequence encoding VEGF-B₁₈₆) and SEQ ID NO:5 (sequence encoding VEGF-B_{Ex1-5}) into which a nucleotide sequence encoding at least one putative N-glycosylation site has been inserted. The nucleic acid molecule having said
20 polynucleotide sequence can be naked and/or in a vector or liposome. The putative N-glycosylation site is -NXT-, -NXS- or -NXC-, where N represents the amino acid asparagine, X may be any amino acid, and T, S and C represent the amino acids threonine, serine and cysteine, respectively. The nucleotide sequence which
25 encodes the N-glycosylation site may thus comprise aay-nnn¹-(wgy/wcn)-nnn², with the proviso that -nnn¹- is not tga, tar or cnn, and -nnn²- is preferably not ccn, where w represents adenine or thymine/uracil, g represents guanine, y represents cytosine or thymine/uracil, c represents cytosine, n represents adenine,
30 cytosine, guanine or thymine/uracil; t represents thymine/uracil, a represents adenine, and r represents guanine or adenine.
(Rules for N-glycosylation are described at

<http://www.expasy.ch/cgi-bin/nicedoc.pl?PDOC00001>). Preferably the nucleotide sequence comprises aay-nnn¹-(agy/wcn)-nnn².

The invention includes the nucleic acid molecules described above as well as fragments of those polynucleotides, and variants of those polynucleotides with sufficient similarity to the non-coding strand of those polynucleotides to hybridize thereto under stringent conditions and which can code for VEGF-B or a fragment or analog thereof which exhibits at least 90% sequence identity to SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5 and which binds to VEGFR-1. Thus, such polynucleotide fragments and variants having a nucleotide sequence encoding at least one putative N-glycosylation site inserted therein are intended as aspects of the invention. Exemplary stringent hybridization conditions are as follows: hybridization at 42°C in 5X SSC, 20 mM NaPO₄, pH 6.8, 50% formamide; and washing at 42°C in 0.2X SSC. Those skilled in the art understand that it is desirable to vary these conditions empirically based on the length and the GC nucleotide base content of the sequences to be hybridized, and that well accepted formulas for determining such variation exist. See for example Sambrook et al, "Molecular Cloning: A Laboratory Manual", Second Edition, pages 9.47-9.51, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory (1989).

Moreover, purified and isolated nucleic acid molecules having a polynucleotide sequence encoding other, non-human, mammalian VEGF-B forms and having a nucleotide sequence encoding at least one putative N-glycosylation site inserted therein are aspects of the invention, as are the polypeptides encoded thereby.

A second aspect of the invention involves the purification and isolation of a protein having an amino acid sequence selected from the group consisting of SEQ ID NO:2 (VEGF-B₁₆₇), SEQ ID NO:4 (VEGF-B₁₈₆) and SEQ ID NO:6 (VEGF-B_{Ex1-5}) and having at least one putative N-glycosylation site inserted therein. The purified and isolated protein preferably is produced by the expression of the

nucleic acid molecule of the invention. As noted above, the at least one putative N-glycosylation site is -NXT-, -NXS- or NXC, where N represents the amino acid asparagine, X may be any amino acid, and T, S and C represent the amino acids threonine, serine and cysteine, respectively. Preferably the N-glycosylation site is -NXT- or -NXS-, especially preferably -NXT-. It is also preferred that X and the amino acid following T or S not be proline.

As used herein, the term "VEGF-B" collectively refers to the known VEGF-B167 and VEGF-B186 polypeptide isoforms as well as to fragments or analogs thereof which exhibit at least 90% sequence identity to SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5 and which bind to VEGFR-1 and/or have the vasculogenesis stimulating activity of VEGF-B. The active substance preferably will include the amino acid sequence Pro-Xaa-Cys-Val-Xaa-Xaa-Xaa-Arg-Cys-Xaa-Gly-Cys-Cys (where Xaa may be any amino acid) which is characteristic of VEGF-B.

Polypeptides comprising conservative substitutions, insertions, or deletions, but which still retain the biological activity of VEGF-B are clearly to be understood to be within the scope of the invention. Persons skilled in the art will be well aware of methods which can readily be used to generate such polypeptides, for example the use of site-directed mutagenesis, or specific enzymatic cleavage and ligation. The skilled person will also be aware that peptidomimetic compounds or compounds in which one or more amino acid residues are replaced by a non-naturally occurring amino acid or an amino acid analog may retain the required aspects of the biological activity of VEGF-B. Such compounds can readily be made and tested by methods known in the art, and are also within the scope of the invention.

In addition, possible variant forms of the VEGF-B polypeptide which may result from alternative splicing, as are known to occur with VEGF and VEGF-B, and naturally-occurring allelic variants of the nucleic acid sequence encoding VEGF-B are

encompassed within the scope of the invention. Allelic variants are well known in the art, and represent alternative forms or a nucleic acid sequence which comprise substitution, deletion or addition of one or more nucleotides, but which do not result in
5 any substantial functional alteration of the encoded polypeptide.

Such variant forms of VEGF-B can be prepared by targeting non-essential regions of the VEGF-B polypeptide for modification. These non-essential regions are expected to fall outside the strongly-conserved regions of the VEGF/PDGF family of growth
10 factors. In particular, the growth factors of the VEGF family, including VEGF-B, are dimeric, and VEGF, VEGF-B, VEGF-C, VEGF-D, PlGF, PDGF-A and PDGF-B show complete conservation of eight cysteine residues in the N-terminal domains, i.e. the PDGF/VEGF-homology domains (Olofsson et al., Proc. Natl. Acad. Sci. USA,
15 1996 93 2576-2581; Joukov et al., EMBO J., 1996 15 290-298). These cysteines are thought to be involved in intra- and inter-molecular disulfide bonding. In addition there are further strongly, but not completely, conserved cysteine residues in the C-terminal domains. Loops 1, 2 and 3 of each subunit, which are
20 formed by intra-molecular disulfide bonding, are involved in binding to the receptors for the PDGF/VEGF family of growth factors (Andersson et al., Growth Factors, 1995 12 159-164).

Persons skilled in the art thus are well aware that in most cases these cysteine residues should be preserved in any proposed
25 variant form, although there may be exceptions since receptor-binding VEGF-B analogs are known in which one or more of the cysteines is not conserved. Similarly, a skilled worker would be aware that the active sites present in loops 1, 2, and 3 also should be preserved. However, other regions of the molecule can
30 be expected to be of lesser importance for biological function, and therefore offer suitable targets for modification. Modified polypeptides can readily be tested for their ability to show the biological activity of VEGF-B by routine activity assay procedures such as the endothelial cell proliferation assay.

Preferably where amino acid substitution is used, the substitution is conservative, i.e. an amino acid is replaced by one of similar size and with similar charge properties. As used herein, the term "conservative substitution" denotes the replacement of an amino acid residue by another, biologically similar residue, i.e., one that has similar properties. Examples of conservative substitutions include the substitution of one hydrophobic residue such as isoleucine, valine, leucine, alanine, cysteine, glycine, phenylalanine, proline, tryptophan, tyrosine, norleucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic acid for aspartic acid, or glutamine for asparagine, and the like. Neutral hydrophilic amino acids which can be substituted for one another include asparagine, glutamine, serine and threonine. The term "conservative substitution" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid. Exemplary conservative substitutions are set out in the following Table A:

Table A

20	Conservative Substitutions I		
	SIDE CHAIN CHARACTERISTIC		AMINO ACID
	Aliphatic		
25	Non-polar	G A P	
		I L V	
	Polar - uncharged	C S T M	
		N Q	
	Polar - charged	D E	
30		K R	
	Aromatic	H F W Y	
	Other	N Q D E	

Alternatively, conservative amino acids can be grouped as described in Lehninger, [Biochemistry, Second Edition; Worth Publishers, Inc. NY:NY (1975), pp.71-77] as set out in the following Table B.

Table B

Conservative Substitutions II

SIDE CHAIN

	CHARACTERISTIC	AMINO ACID
5	Non-polar (hydrophobic)	
	A. Aliphatic:	A L I V P
	B. Aromatic:	F W
	C. Sulfur-containing:	M
10	D. Borderline:	G
	Uncharged-polar	
	A. Hydroxyl:	S T Y
	B. Amides:	N Q
	C. Sulfhydryl:	C
15	D. Borderline:	G
	Positively Charged (Basic):	K R H
	Negatively Charged (Acidic):	D E

Exemplary conservative substitutions also are set out in the
 20 following Table C.

Table C

Conservative Substitutions III

	<u>Original Residue</u>	<u>Exemplary Substitution</u>
5	Ala (A)	Val, Leu, Ile
	Arg (R)	Lys, Gln, Asn
	Asn (N)	Gln, His, Lys, Arg
	Asp (D)	Glu
	Cys (C)	Ser
10	Gln (Q)	Asn
	Glu (E)	Asp
	His (H)	Asn, Gln, Lys, Arg
	Ile (I)	Leu, Val, Met, Ala, Phe,
	Leu (L)	Ile, Val, Met, Ala, Phe
15	Lys (K)	Arg, Gln, Asn
	Met (M)	Leu, Phe, Ile
	Phe (F)	Leu, Val, Ile, Ala
	Pro (P)	Gly
	Ser (S)	Thr
20	Thr (T)	Ser
	Trp (W)	Tyr, Phe
	Tyr (Y)	Trp, Phe, Thr, Ser
	Val (V)	Ile, Leu, Met, Phe, Ala

25 If desired, the VEGF-B proteins of the invention can be modified, for instance, by amidation, carboxylation, or phosphorylation, or by the creation of acid addition salts, amides, esters, in particular C-terminal esters, and N-acyl derivatives of the peptides of the invention. The proteins also

can be modified to create peptide derivatives by forming covalent or noncovalent complexes with other moieties. Covalently-bound complexes can be prepared by linking the chemical moieties to functional groups on the side chains of amino acids comprising
5 the peptides, or at the N- or C-terminus.

In particular, it is anticipated that the VEGF-B proteins can be conjugated to a reporter group, including, but not limited to a radiolabel, a fluorescent label, an enzyme (e.g., that catalyzes a colorimetric or fluorometric reaction), a substrate,
10 a solid matrix, or a carrier (e.g., biotin or avidin). The polypeptide can be linked to an epitope tag, such as the FLAG[®] octapeptide (Sigma, St. Louis, MO) or histidine, to assist in affinity purification. Also the polypeptides according to the invention may be labeled with a detectable label. The
15 polypeptide may be covalently or non-covalently coupled to a suitable supermagnetic, paramagnetic, electron dense, ecogenic or radioactive agent for imaging. For use in diagnostic assays, radioactive or non-radioactive labels may be used. Examples of radioactive labels include a radioactive atom or group, such as
20 ¹²⁵I or ³²P. Examples of non-radioactive labels include enzymatic labels, such as horseradish peroxidase or fluorimetric labels, such as fluorescein-5-isothiocyanate (FITC). Labeling may be direct or indirect, covalent or non-covalent.

The modified polypeptides can readily be tested for their
25 ability to show the biological activity of VEGF-B by routine activity assay procedures such as the fibroblast proliferation assay.

It will be clearly understood that nucleic acids and polypeptides of the invention may be prepared by synthetic means
30 or by recombinant means, or may be purified from natural sources.

As used herein, the term "comprising" means "included but not limited to". The corresponding meaning applies to the word "comprises".

A third aspect of the invention provides vectors comprising the nucleic acid molecule of the first aspect of the invention, and host cells transformed or transfected with nucleic acids molecules or vectors of the invention. These may be eukaryotic or prokaryotic in origin. These cells are particularly suitable for expression of the polypeptide of the invention, and include insect cells such as Sf9 or HF cells, obtainable from the American Type Culture Collection, infected with a recombinant baculovirus, and the human embryo kidney cell line 293-EBNA transfected by a suitable expression plasmid. Preferred vectors of the invention are expression vectors in which a nucleic acid according to the invention is operatively connected to one or more appropriate promoters and/or other control sequences, such that appropriate host cells transformed or transfected with the vectors are capable of expressing the polypeptide of the invention. Other preferred vectors are those suitable for transfection of mammalian cells, or for gene therapy, such as adenoviral-, vaccinia- or retroviral-based vectors or liposomes. A variety of such vectors are known in the art.

The invention also provides a method of making a vector capable of expressing a polypeptide encoded by a nucleic acid according to the invention, comprising the steps of operatively connecting the nucleic acid molecule of the first aspect to one or more appropriate promoters and/or other control sequences, as described above.

The invention further provides a method of making a polypeptide according to the invention, comprising the steps of expressing a nucleic acid or vector of the invention in a host cell, and isolating the polypeptide from the host cell or from the host cell's growth medium.

The polypeptide according to the invention may be employed in combination with a suitable pharmaceutical carrier. The resulting compositions comprise an effective amount of

glycosylated VEGF-B or a pharmaceutically acceptable non-toxic salt thereof, and a pharmaceutically acceptable solid or liquid carrier or adjuvant. Examples of such a carrier or adjuvant include, but are not limited to, saline, buffered saline, 5 Ringer's solution, mineral oil, talc, corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, alginic acid, dextrose, water, glycerol, ethanol, thickeners, stabilizers, suspending agents and combinations thereof. Such compositions may be in the 10 form of solutions, suspensions, tablets, capsules, creams, salves, elixirs, syrups, wafers, ointments or other conventional forms. The formulation to suit the mode of administration. Compositions can comprise a glycosylated VEGF-B and optionally further comprise one or more of PDGF-A, PDGF-B, VEGF, non- 15 glycosylated VEGF-B, VEGF-C, VEGF-D, PlGF and/or heparin. Compositions comprising the glycosylated VEGF-B will contain from about 0.1% to 90% by weight of the active compound(s), and most generally from about 10% to 30%.

For intramuscular preparations, a sterile formulation, 20 preferably a suitable soluble salt form of the glycosylated VEGF-B, such as hydrochloride salt, can be dissolved and administered in a pharmaceutical diluent such as pyrogen-free water (distilled), physiological saline or 5% glucose solution. A suitable insoluble form of the compound may be prepared and 25 administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, e.g. an ester of a long chain fatty acid such as ethyl oleate.

In a further aspect, the invention provides a method for making a soluble VEGF-B₁₆₇ from a host cell and a method for 30 increasing an amount of a soluble VEGF-B₁₆₇, VEGF-B₁₈₆ or VEGF-B_{Ex1-5} protein from a host cell. These methods comprise inserting at least one putative N-glycosylation site into a nucleotide sequence which codes for VEGF-B₁₆₇, VEGF-B₁₈₆ or VEGF-B_{Ex1-5} protein;

transforming or transfecting said nucleotide sequence with the inserted N-glycosylation site into a host cell; culturing the transfected host cell in a growth medium such that said nucleotide sequence with inserted N-glycosylation site is
5 expressed; and isolating the expressed polypeptide from the growth medium in which said host cell was cultured. These methods can further comprise exposing the cultured transfected host cell to heparin after said polypeptide is expressed.

10 BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be described in further detail hereinafter with reference to the accompanying drawings in which:

Fig. 1 is an alignment of the amino acid sequences of the VEGF homology domain (VHD) of VEGF-A and PlGF with VEGF-B;

15 Fig. 2 is a diagram of plasmid pSecTagA-hVEGF-B₁₈₆-H₆-NXT containing a nucleotide sequence encoding VEGF-B₁₈₆ having an N-glycosylation site incorporated therein;

Fig. 3 is a diagram of plasmid pSecTagA-hVEGF-B₁₆₇-H₆-NXT containing a nucleotide sequence encoding VEGF-B₁₆₇ having an
20 N-glycosylation site incorporated therein;

Fig. 4 is a diagram of plasmid pSecTagA-hVEGF-B-Exon1-5-H₆-NXT containing a nucleotide sequence encoding exons 1-5 of VEGF-B having an N-glycosylation site incorporated therein;

Fig. 5 shows the expression of hVEGF-B₁₆₇ with and without
25 the potential glycosylation site (NXT);

Fig. 6 shows the expression of hVEGF-B₁₆₇ and hVEGF-B₁₈₆ with and without the potential glycosylation site (NXT);

Fig. 7 shows the expression and receptor binding of hVEGF-B₁₆₇ and hVEGF-B₁₈₆ with and without the potential glycosylation
30 site (NXT); and

Fig. 8 shows the expression and receptor binding of polypeptide encoded by exons 1-5 of hVEGF-B with and without the potential glycosylation site (NXT).

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Example 1: Introduction of the glycosylation site

5 As mentioned before, VEGF-B is a PDGF/VEGF family member that is completely devoid of any N-glycosylation. To analyze the effects of N-glycosylation on VEGF-B, a N-glycosylation site was introduced into VEGF-B. To determine the most appropriate site to introduce a mutation that would lead to N-glycosylation of
10 VEGF-B, the amino acid sequences of the first 99 amino acids of VEGF-A, PlGF and VEGF-B, respectively, were aligned (see Fig. 1). The N-glycosylation sites of VEGF-A and PlGF at amino acids 65-67 are italicized in Fig. 1. Nucleotides encoding a putative N-glycosylation site (NXT) were inserted at the position
15 corresponding to nucleotides 286-294 of hVEGF-B (SEQ ID NO:1). The replaced nucleotides normally found at positions 286-294 encode the amino acid residues QVR and these amino acid residues are bolded in Fig. 1.

20 Example 2: Preparation of Recombinant Vectors

Six mammalian expression vectors for both naturally occurring isoforms of VEGF-B (i.e., VEGF-B₁₆₇ and VEGF-B₁₈₆) and for an artificial splice variant (comprising exons 1 to 5 only) were constructed with and without the putative N-glycosylation
25 site.

Using PCR, nucleotides coding for a histidine tag were added to the C-terminal end of a nucleotide sequence coding for hVEGF-B₁₈₆. A nucleotide sequence coding for hVEGF-B₁₈₆-H₆ was then inserted into pSecTagA (Invitrogen, Carlsbad, California) using
30 standard cloning procedures to construct pSecTagA-hVEGF-B₁₈₆-H₆. The full sequence of pSecTagA-hVEGF-B₁₈₆-H₆ is given in SEQ ID NO:7.

To construct pSecTagA-hVEGF-B₁₆₇-H₆, a 349 bp PCR product was produced covering nucleotides 250-567 from Genebank Acc. No. U48801, nucleotides coding for the histidine tag, a stop codon, the NotI restriction site and terminal clamp nucleotides using the 5' primer: 5'-CCTGACGATGGCCTGGAGTGT-3' (SEQ ID NO:10) and the 3' primer: 5'-GAGCGGCCGCTCAATGATGATGATGATGATGCCTTCGCAGCTTCCGGCAC-3' (SEQ ID NO:11) and hVEGF-B₁₆₇ as the template. The 349 bp PCR product was cut with KpnI and NotI and the KpnI-NotI fragment was inserted into pSecTagA-hVEGF-B₁₈₆-H₆ to replace the KpnI-NotI fragment removed from this vector using standard cloning procedures. The full sequence of pSecTagA-hVEGF-B₁₆₇-H₆ is given in SEQ ID NO:12.

- 24 -

To construct pSecTagA-hVEGF-B_{Ex1-5}-H₆, a 443 bp PCR product was obtained covering nucleotides 1-411 from Genbank Acc. No. U48801, nucleotides coding for the histidine tag, a stop codon, the NotI restriction site and terminal clamp nucleotides using the 5' primer: 5'-CACCATGAGCCCTCTGCTCC-3' (SEQ ID NO:14) and 3' primer: 5'-GAGCGGCCGCTCAGTGGTGATGATGATGGTCTGGCTTCACAGCACTG-3' (SEQ ID NO:15) and hVEGF-B₁₆₇ as the template. The PCR product was cut with KpnI and NotI and the resulting 320 bp fragment was inserted into pSecTagA-hVEGF-B₁₈₆-H₆-NXT to replace the KpnI-NotI removed from this vector using standard cloning procedures. The full sequence of pSecTagA-hVEGF-B_{Ex1-5}-H₆ is given in SEQ ID NO:16.

To construct pSecTagA-hVEGF-B_{Ex1-5}-H₆-NXT, the same procedures as above were used except the KpnI-NotI fragment was inserted into pSecTagA-hVEGF-B₁₈₆-H₆-NXT to replace the KpnI-NotI fragment removed from this vector. The full sequence of pSecTagA-hVEGF-B_{Ex1-5}-H₆-NXT is given in SEQ ID NO:17, and the plasmid is illustrated in Fig. 4.

The following Table D lists the expression vectors for the naturally occurring 186 and 167 amino acid isoforms of VEGF-B and for the artificial splice variant (comprising exon 1 to 5 only), constructed with and without the potential glycosylation site (NXT).

Table D

	Construct Name	Protein
5	pSecTagA-hVEGF-B ₁₈₆ -H ₆	histidine-tagged VEGF-B ₁₈₆
	pSecTagA-hVEGF-B ₁₈₆ -H ₆ -NXT	histidine-tagged and N-glycosylated VEGF-B ₁₈₆
10	pSecTagA-hVEGF-B ₁₆₇ -H ₆	histidine-tagged VEGF-B ₁₆₇
	pSecTagA-hVEGF-B ₁₆₇ -H ₆ -NXT	histidine-tagged and N-glycosylated VEGF-B ₁₆₇
15	pSecTagA-hVEGF-B-Exon1-5-H ₆	histidine-tagged VEGF-B Exons 1 to 5 only
	pSecTagA-hVEGF-B-Exon1-5-H ₆ -NXT	histidine-tagged and N-glycosylated VEGF-B Exons 1 to 5 only

20

Example 3: Transfection and Expression of Recombinant Proteins

The six mammalian expression vectors of human VEGF-B described above along with expression vectors containing histidine-tagged VEGF (positive control), a histidine-tagged VHD of VEGF-C (negative control) and histidine-tagged hybrid 84-11 (positive control), respectively, were transfected into 293T cells using CaPO₄-mediated transfection according to procedures described in Sambrook, J. et al., Molecular Cloning, A Laboratory Manual, (Cold Spring Harbor Press, Cold Spring Harbor, NY), 25 16.33-16.36 (1989). 48 hours after transfection, the cells were metabolically labeled with S³⁵ methionine and S³⁵ cysteine (Promix, Amersham) for 12 to 24 hours. The conditioned supernatant was subjected to immunoprecipitation with an

antiserum specific to human VEGF-B (874) and a monoclonal antibody specific to pentahistidine (H_5 mAb, Qiagen).

As seen in Figs. 5 through 8, the three constructs produced with the inserted putative N-glycosylation site are glycosylated.

5 As can be seen from Figs. 5-7, comparison of supernatants and lysates and using heparin to release cell bound proteins shows that VEGF-B₁₆₇ is almost completely retained at the cell surface or within the cell. About a 50 fold increase of VEGF-B₁₆₇ can be detected in the supernatant upon glycosylation (Fig. 5).
10 As shown in Figs. 6 and 7, VEGF-B₁₆₇ is released into the supernatant by treatment with 100 μ g/ml heparin two hours prior to harvest. It was also found that approximately two times more glycosylated VEGF-B₁₆₇ can be detected in the supernatant of non-heparin treated 293T cells as compared to non-glycosylated VEGF-
15 B₁₆₇ treated with 200 μ g/ml heparin for two hours prior to harvesting. In addition, there is about a three fold increase in the amount of the glycosylated VEGF-B₁₆₇ detected in the supernatant by treatment with 200 μ g/ml heparin two hours prior to harvest as compared to glycosylated VEGF-B₁₆₇ without heparin
20 treatment, and approximately a six fold increase in the amount of the glycosylated VEGF-B₁₆₇ detected in the supernatant by treatment with 200 μ g/ml heparin two hours prior to harvest as compared to the amount of non-glycosylated VEGF-B₁₆₇ detected in the supernatant with the same heparin treatment.

25 Figs. 6 and 7 show that VEGF-B₁₈₆ is also partially retained at the cell surface and within the cell. In contrast to VEGF-B₁₆₇, almost all of the VEGF-B₁₈₆ is released into the supernatant upon glycosylation and heparin treatment (Figs. 6 and 7). There seems to be no significant difference in the amount of VEGF-B₁₈₆
30 found in the supernatant between heparin-treated and untreated 293T cells. Thus the difference of VEGF-B₁₈₆ and N-glycosylated VEGF-B₁₈₆ protein levels in the supernatant (approximately three times more glycosylated VEGF-B₁₈₆) seems to be mainly due to

enhanced secretion and/or production and not due to the release of cell surface bound protein.

Fig. 8 shows that VEGF-B_{Exon1-5} is only efficiently released into the medium if it is N-glycosylated (over a 50 fold increase in soluble protein). This is unexpected since the signals retaining VEGF-B at the cell surface are thought to reside in the exon 6 and 7 encoded domains (Fig. 8). Treatment with heparin was not determined for this same reason.

10 Example 4: VEGF receptor 1 binding of recombinant proteins

The ability of the recombinant VEGF-B to bind VEGF receptor 1 (VEGFR-1) was analyzed using soluble fusion proteins consisting of the extracellular domain of VEGFR-1 and the Fc portion of human IgG1 (VEGFR-1-Fc). Biosynthetically labeled conditioned medium derived from 293T cells transfected as above in Example 3 were immunoprecipitated with protein A sepharose (PAS) bound to the VEGFR-1-Ig. Beads were washed three times with PBS, the bound protein eluted and resolved by reducing SDS-PAGE (15%). The dried gels were exposed to phosphorimager plates for 12-24 hours. Additionally, the cell lysates were immunoprecipitated with H₅ mAb.

When significant amounts of VEGF-B were present in the supernatant, binding to VEGFR-1 could be observed. This was seen with VEGF-B₁₈₆-H₅ after treatment with 100 µg/ml heparin two hours prior to harvest, VEGF-B₁₈₆-NXT-H₅ and VEGF-B Exon 1-5-NXT-H₅ (Figs. 7 and 8).

Example 5: Stimulation of BaF3 VEGFR-01EC/EpoR Cell Survival

The effects of introducing the N-glycosylation site into VEGF-B can be assayed by measuring the ability of conditioned media from cells transfected with VEGF-B167 and VEGF-B167-NXT and/or VEGF-B186 and VEGF-B186-NXT to stimulate the survival of BaF3 VEGFR-01EC/EpoR cells. For the assay, BaF3 cells are used

that are stably transfected with a chimeric receptor consisting of the extracellular domain of VEGF receptor 1 and the intracellular domain of the erythropoietin receptor. For survival, these cells need either interleukin-3 or any growth factor capable of binding VEGFR-1, e.g., VEGF-A, VEGF-B or PlGF. Cells are plated to 96-well plates at a density of 20,000/well and grown in the presence of different amounts of medium conditioned by 293T cells that have been transfected with VEGF-B167 and VEGF-B167-NXT, VEGF-B186 and VEGF-B186-NXT, or both. Conditioned medium from 293T cells transfected with a mock (i.e., empty) vector may be used as a control. Prior to the assay, the conditioned medium should be cleared from potentially interfering proteins by immunoprecipitation using appropriate antibodies. For example, VEGF-A may be cleared from the conditioned medium prior to the assay using a mixture of monoclonal and polyclonal anti-hVEGF antibodies, commercially available from R&D Systems, Minneapolis, Minnesota. It is not necessary to preclear medium of PlGF as the amounts expressed by COS cells (if any) are negligible and its effects are not visible in the baseline noise. After 48 hours, an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide thiazole blue) colorimetric assay may be performed and data collected at 540 nm using a microtitreplate reader.

To create the BglII site in the coding sequence of human VEGFR-1 just before the transmembrane domain, basepairs 1998-2268 of VEGFR-1 were PCR amplified with primers 5'-CCTCAGTGATCACACAGTGG-3', containing the endogenous BclI site, and 5'-CAGAGATCTATTAGACTTGTCC-3', containing a BglII site, and the PCR fragment was cloned into the BclI-BglII sites of VEGFR-1 in pBlueScript SKII+ (Stratagene) vector. The transmembrane and intracellular domains of the human erythropoietin receptor were excised from EpoR x B+B/pcDNAI and subcloned into the resulting plasmid as a BglII/NotI fragment. The EpoR x B+B is a clone of

EpoR which has an internal BglII site added at the putative transmembrane (TM)/extracellular (EC) domain junction for the in-frame ligation of RTK extracellular domains. The vector backbone is pCDNA1-amp (~5.4 kb, the original 1.75 kb EpoR clone was 5 subcloned into pCDNA1-amp using KpnI, the sequence was reported by the Lodish Laboratory, MIT). An ~1 kb fragment can be excised from this clone using BglII (5') - NotI (3') digest which contains the TM and cytoplasmic domain of EpoR.

The VEGFR-1/EpoR construct was finally subcloned into the 10 pEF-BOS vector (Mizushima et al., Nucleic Acids Research, 18(17):5322 Sept. 11, 1990) as a KpnI/NotI fragment. The resulting plasmid was electroporated into BaF3 cells and stable cell pools were generated by selection with 250 micrograms/mL zoecin.

15 The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the disclosed embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the invention should be construed 20 broadly to include everything within the scope of the appended claims and equivalents thereof.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising:
a polynucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or a polynucleotide sequence which hybridizes under stringent conditions with at least one of the foregoing sequences; and
a nucleotide sequence encoding at least one putative N-glycosylation site inserted therein.
2. An isolated polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6 and having at least one putative N-glycosylation site inserted therein.
3. The isolated nucleic acid molecule of claim 1, wherein the at least one putative N-glycosylation site consists of a nucleotide sequence that encodes an amino acid sequence of NXT.
4. The isolated nucleic acid molecule of claim 1, wherein the at least one putative N-glycosylation site is inserted at nucleotides 286-294 of SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5.
5. An isolated polypeptide produced by expression of the nucleic acid molecule of claim 1.
6. An isolated polypeptide of claim 2 which binds a Vascular Endothelial Growth Factor Receptor-1.
7. A vector comprising a nucleic acid molecule of claim 1.

8. A host cell transformed or transfected with a vector according to claim 7.

9. A pharmaceutical composition comprising an effective amount of a polypeptide of claim 2.

10. The pharmaceutical composition of claim 9, further comprising heparin.

11. A method of making a soluble VEGF-B₁₆₇ from a host cell, comprising:

inserting at least one putative N-glycosylation site into a nucleotide sequence of SEQ ID NO:1;

transforming or transfecting said nucleotide sequence with inserted N-glycosylation site into a host cell;

culturing the transfected host cell in a growth medium such that said nucleotide sequence with inserted N-glycosylation site is expressed; and

isolating the expressed polypeptide from the growth medium in which said host cell was cultured.

12. The method of claim 11, further comprising exposing the cultured transfected host cell to heparin after said polypeptide is expressed.

13. The method of claim 11, wherein the at least one putative N-glycosylation site consists of a nucleotide sequence that encodes an amino acid sequence of NXT.

14. The method of claim 11, wherein the nucleotide sequence encoding the at least one putative N-glycosylation site is inserted at nucleotides 286-294 of SEQ ID NO:1.

15. A method of increasing an amount of a soluble VEGF-B₁₆₇, VEGF-B₁₈₆ or VEGF-B_{Ex1-5} polypeptide from a host cell, comprising:
inserting at least one putative N-glycosylation site into a nucleotide sequence selected from the group of nucleotides sequences of SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5;

transforming or transfecting said nucleotide sequence with inserted N-glycosylation site into a host cell;

culturing the transfected host cell in a growth medium such that said nucleotide sequence with inserted N-glycosylation site is expressed; and

isolating the expressed polypeptide from the growth medium in which said host cell was cultured.

16. The method of claim 15, further comprising exposing the cultured transfected host cell to heparin after said polypeptide is expressed.

17. The method of claim 15, wherein the at least one putative N-glycosylation site consists of a nucleotide sequence that encodes an amino acid sequence of NXT.

18. The method of claim 15, wherein the nucleotide sequence encoding the at least one putative N-glycosylation site is inserted at nucleotides 286-294 of SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5.

Fig. 1

hVEGF-A	1	HHEVVKFMDV	YQSYCHPIE	TLVDIFQEYP	DEIEYIFKPS	CVPLMRCGGC	50
hPIGF	1	EVEVVPFQEV	WGRSYCRAL	RLVDVVSEYP	SEVEHMFSPS	CVSLLRCTGC	50
hVEGF-B	1	QRKVVSVIDV	YTRATCQPRE	VVPLTVELM	GTVAKQLVPS	CVTVQRCGGC	50
hVEGF-A	51	CNDEGLECVP	TEESNITMQI	MRIKPHQGGH	IGEMSFLQHN	KCECRPKK-D	99
hPIGF	51	CGDEDLHCVP	VETANVTMQL	LKIRSGDRPS	YVELTFSQHV	RCECRPLR-E	99
hVEGF-B	51	CPDDGLECVP	TGQHQRVMQI	LMIR-YPSSQ	LGEMSLEEHS	QCECRPKK-D	99




Fig. 2




Fig. 3





Fig. 4






Fig. 6




Fig. 7




Fig. 8

SEQUENCE LISTING

<110> JELTSCH, Markku M

ALITALO, Kari

OLOFSSON, Birgitta

ERIKSSON, Ulf

<120> GLYCOSYLATED VEGF-B AND METHOD FOR INCEREASING THE
AMOUNT OF SOLUBLE VEGF-B

<130> 1064-48929PV Markku JELTSCH et al

<140>

<141>

<160> 17

<170> PatentIn Ver. 2.0

<210> 1

<211> 567

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(567)

<220>

<221> mat_peptide

<222> (64)..(564)

<400> 1

atg agc cct ctg ctc cgc cgc ctg ctg ctc gcc gca ctc ctg cag ctg 48

Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala Leu Leu Gln Leu

-20

-15

-10

gcc ccc gcc cag gcc cct gtc tcc cag cct gat gcc cct ggc cac cag 96

Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln

-5

-1 1

5

10

agg aaa gtg gtg tca tgg ata gat gtg tat act cgc gct acc tgc cag 144

Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys Gln

15

20

25

ccc egg gag gtg gtg gtg ccc ttg act gtg gag ctc atg ggc acc gtg 192

Pro Arg Glu Val Val Val Pro Leu Thr Val Glu Leu Met Gly Thr Val

30

35

40

gcc aaa cag ctg gtg ccc agc tgc gtg act gtg cag cgc tgt ggt ggc 240

Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly

45

50

55

tgc tgc cct gac gat ggc ctg gag tgt gtg ccc act ggg cag cac caa 288

Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln

60

65

70

75

gtc cgg atg cag atc ctc atg atc cgg tac ccg agc agt cag ctg ggg 336

Val Arg Met Gln Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu Gly

80

85

90

gag atg tcc ctg gaa gaa cac agc cag tgt gaa tgc aga cct aaa aaa 384

Glu Met Ser Leu Glu Glu His Ser Gln Cys Glu Cys Arg Pro Lys Lys

95

100

105

aag gac agt gct gtg aag cca gac agc ccc agg ccc ctc tgc cca cgc 432

Lys Asp Ser Ala Val Lys Pro Asp Ser Pro Arg Pro Leu Cys Pro Arg

110

115

120

tgc acc cag cac cac cag cgc cct gac ccc cgg acc tgc cgc tgc cgc 480

Cys Thr Gln His His Gln Arg Pro Asp Pro Arg Thr Cys Arg Cys Arg

125

130

135

tgc cga cgc cgc agc ttc ctc cgt tgc caa ggg cgg ggc tta gag ctc 528

Cys Arg Arg Arg Ser Phe Leu Arg Cys Gln Gly Arg Gly Leu Glu Leu

140

145

150

155

aac cca gac acc tgc agg tgc cgg aag ctg cga agg tga

567

Asn Pro Asp Thr Cys Arg Cys Arg Lys Leu Arg Arg

160

165

<210> 2

<211> 188

<212> PRT

<213> Homo sapiens

<400> 2

Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala Leu Leu Gln Leu

1

5

10

15

Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln

20 25 30
Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys Gln
35 40 45
Pro Arg Glu Val Val Val Pro Leu Thr Val Glu Leu Met Gly Thr Val
50 55 60
Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly
65 70 75 80
Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln
85 90 95
Val Arg Met Gln Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu Gly
100 105 110
Glu Met Ser Leu Glu Glu His Ser Gln Cys Glu Cys Arg Pro Lys Lys
115 120 125
Lys Asp Ser Ala Val Lys Pro Asp Ser Pro Arg Pro Leu Cys Pro Arg
130 135 140
Cys Thr Gln His His Gln Arg Pro Asp Pro Arg Thr Cys Arg Cys Arg
145 150 155 160
Cys Arg Arg Arg Ser Phe Leu Arg Cys Gln Gly Arg Gly Leu Glu Leu
165 170 175
Asn Pro Asp Thr Cys Arg Cys Arg Lys Leu Arg Arg

180

185

<210> 3

<211> 624

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(621)

<220>

<221> mat_peptide

<222> (64)..(621)

<400> 3

atg agc cct ctg ctc cgc cgc ctg ctg ctc gcc gca ctc ctg cag ctg 48

Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala Leu Leu Gln Leu

-20

-15

-10

gcc ccc gcc cag gcc cct gtc tcc cag cct gat gcc cct ggc cac cag 96

Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln

-5

-1 1

5

10

agg aaa gtg gtg tca tgg ata gat gtg tat act cgc gct acc tgc cag 144

Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys Gln

15

20

25

ccc cgg gag gtg gtg gtg ccc ttg act gtg gag ctc atg ggc acc gtg 192

Pro Arg Glu Val Val Val Pro Leu Thr Val Glu Leu Met Gly Thr Val

30	35	40	
gcc aaa cag ctg gtg ccc agc tgc gtg act gtg cag cgc tgt ggt ggc 240			
Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly			
45	50	55	
tgc tgc cct gac gat ggc ctg gag tgt gtg ccc act ggg cag cac caa 288			
Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln			
60	65	70	75
gtc cgg atg cag atc ctc atg atc cgg tac ccg agc agt cag ctg ggg 336			
Val Arg Met Gln Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu Gly			
80	85	90	
gag atg tcc ctg gaa gaa cac agc cag tgt gaa tgc aga cct aaa aaa 384			
Glu Met Ser Leu Glu Glu His Ser Gln Cys Glu Cys Arg Pro Lys Lys			
95	100	105	
aag gac agt gct gtg aag cca gac agg gct gcc act ccc cac cac cgt 432			
Lys Asp Ser Ala Val Lys Pro Asp Arg Ala Ala Thr Pro His His Arg			
110	115	120	
ccc cag ccc cgt tct gtt ccg ggc tgg gac tct gcc ccc gga gca ccc 480			
Pro Gln Pro Arg Ser Val Pro Gly Trp Asp Ser Ala Pro Gly Ala Pro			
125	130	135	
tcc cca gct gac atc acc cat ccc act cca gcc cca ggc ccc tct gcc 528			
Ser Pro Ala Asp Ile Thr His Pro Thr Pro Ala Pro Gly Pro Ser Ala			
140	145	150	155

cac gct gca ccc agc acc acc agc gcc ctg acc ccc gga cct gcc gcc 576

His Ala Ala Pro Ser Thr Thr Ser Ala Leu Thr Pro Gly Pro Ala Ala

160

165

170

gcc gct gcc gac gcc gca gct tcc tcc gtt gcc aag ggc ggg gct tag 624

Ala Ala Ala Asp Ala Ala Ala Ser Ser Val Ala Lys Gly Gly Ala

175

180

185

<210> 4

<211> 207

<212> PRT

<213> Homo sapiens

<400> 4

Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala Leu Leu Gln Leu

-20

-15

-10

Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln

-5

-1 1

5

10

Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys Gln

15

20

25

Pro Arg Glu Val Val Val Pro Leu Thr Val Glu Leu Met Gly Thr Val

30

35

40

Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly

45

50

55

Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln

60 65 70 75

Val Arg Met Gln Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu Gly

80 85 90

Glu Met Ser Leu Glu Glu His Ser Gln Cys Glu Cys Arg Pro Lys Lys

95 100 105

Lys Asp Ser Ala Val Lys Pro Asp Arg Ala Ala Thr Pro His His Arg

110 115 120

Pro Gln Pro Arg Ser Val Pro Gly Trp Asp Ser Ala Pro Gly Ala Pro

125 130 135

Ser Pro Ala Asp Ile Thr His Pro Thr Pro Ala Pro Gly Pro Ser Ala

140 145 150 155

His Ala Ala Pro Ser Thr Thr Ser Ala Leu Thr Pro Gly Pro Ala Ala

160 165 170

Ala Ala Ala Asp Ala Ala Ala Ser Ser Val Ala Lys Gly Gly Ala

175 180 185

<210> 5

<211> 408

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(408)

<220>

<221> mat_peptide

<222> (64)..(408)

<400> 5

atg agc cct ctg ctc cgc cgc ctg ctg ctc gcc gca ctc ctg cag ctg 48

Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala Leu Leu Gln Leu

-20

-15

-10

gcc ccc gcc cag gcc cct gtc tcc cag cct gat gcc cct ggc cac cag 96

Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln

-5

-1 1

5

10

agg aaa gtg gtg tca tgg ata gat gtg tat act cgc gct acc tgc cag 144

Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys Gln

15

20

25

ccc cgg gag gtg gtg gtg ccc ttg act gtg gag ctc atg ggc acc gtg 192

Pro Arg Glu Val Val Val Pro Leu Thr Val Glu Leu Met Gly Thr Val

30

35

40

gcc aaa cag ctg gtg ccc agc tgc gtg act gtg cag cgc tgt ggt ggc 240

Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly

45

50

55

tgc tgc cct gac gat ggc ctg gag tgt gtg ccc act ggg cag cac caa 288

Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln

60

65

70

75

gtc cgg atg cag atc ctc atg atc cgg tac ccg agc agt cag ctg ggg 336

Val Arg Met Gln Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu Gly

80

85

90

gag atg tcc ctg gaa gaa cac agc cag tgt gaa tgc aga cct aaa aaa 384

Glu Met Ser Leu Glu Glu His Ser Gln Cys Glu Cys Arg Pro Lys Lys

95

100

105

aag gac agt gct gtg aag cca gac

408

Lys Asp Ser Ala Val Lys Pro Asp

110

115

<210> 6

<211> 136

<212> PRT

<213> Homo sapiens

<400> 6

Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala Leu Leu Gln Leu

-20

-15

-10

Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln

-5

-1 1

5

10

Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys Gln

15

20

25

Pro Arg Glu Val Val Val Pro Leu Thr Val Glu Leu Met Gly Thr Val

30 35 40

Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly

45 50 55

Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln

60 65 70 75

Val Arg Met Gln Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu Gly

80 85 90

Glu Met Ser Leu Glu Glu His Ser Gln Cys Glu Cys Arg Pro Lys Lys

95 100 105

Lys Asp Ser Ala Val Lys Pro Asp

110 115

<210> 7

<211> 5614

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

pSecTagA-VEGF-B167-H6

<400> 7

gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60

ccgcatagtt aagccagtat ctgctccctg cttgtgtggt ggaggtcgct gagtagtgcg 120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagtcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360
cccgeccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgcca cttggcagta catcaagtgt 480
atcatatgcc aagtacgcc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgccagta catgacctta tgggactttc ctacttgga gtacatctac gtattagtca 600
tcgtattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccaccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgctga acaactccgc ccattgacg caaatgggcg 780
gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaacca 840
ctgcttactg gcttatcgaa attaatacga ctactatag ggagaccaa gctggctagt 900
ccagtgtggt ggaattcggc ttcacatga gccctctgct ccgcgcctg ctgctcgccg 960
cactcctgca gctggccccc gccaggccc ctgtctcca gctgatgcc cctggccacc 1020

agaggaaagt ggtgtcatgg atagatgtgt atactcgcg tacctgccag ccccgaggag 1080

tggtggtgcc cttgactgtg gagctcatgg gcaccgtggc caaacagctg gtgcccagct 1140

gcgtgactgt gcagcgctgt ggtggctgct gccctgacga tggcctggag tgtgtgcca 1200

ctgggcagca ccaagtccgg atgcagatcc tcatgatccg gtacccgagc agtcagctgg 1260

gggagatgtc cctggaagaa cacagccagt gtgaatgcag acctaaaaa aaggacagtg 1320

ctgtgaagcc agacagcccc agggccctct gccacgctg caccagcac caccagcgcc 1380

ctgacccccg gacctgccgc tgccgtgcc gacgccgag ctctctccgt tgccaagggc 1440

ggggcttaga gctcaacca gacacctgca ggtgccggaa gctgcgaagg catcatcatc 1500

atcatcattg agcgcccgct cgagtctaga gggcccgaac aaaaactcat ctgagaagag 1560

gatctgaata gcgcgctga ccatcatcat catcatcatt gagtttaaac ccgctgatca 1620

gcctcgactg tgccctctag ttgccagcca tctgttgttt gcccctccc cgtgccttec 1680

ttgacctgg aaggtgccac tccactgtc ctttcctaataaaaatgagga aattgcatcg 1740

cattgtctga gtaggtgtca ttctattctg ggggggtggg tggggcagga cagcaagggg 1800

gaggattggg aagacaatag caggcatgct ggggatgcgg tgggtcttat ggcttctgag 1860

gcggaaagaa ccagctgggg ctctagggg tatccccacg cgccctgtag cggcgcatca 1920

agcgcggcgg gtgtggtggt tacgcgcagc gtgaccgcta cacttgccag cgccctagcg 1980

cccgtccctt tcgctttctt cccttccttt ctgccacgt tcgccggctt tccccgtcaa 2040

gctctaaatc ggggcatccc tttagggttc cgatttagtg ctttacggca cctcgacccc 2100

aaaaaacttg attagggtga tggttcacgt agtgggcat cgccctgata gacggttttt 2160

cgccctttga cgttgagtc cacgttcttt aatagtggac tcttgttcca aactggaaca 2220

acactcaacc ctatctcggc ctattctttt gatttataag ggattttggg gatttcggcc 2280

tattggttaa aaaatgagct gatttaacaa aaatttaacg cgaattaatt ctgtggaatg 2340

tgtgtcagtt aggggtgga aagtcgccag gtcgccagc aggcagaagt atgcaaagca 2400

tgcattctca ttagtcagca accaggtgtg gaaagtcccc aggtcccca gcaggcagaa 2460

gtagcacaag catgcatctc aattagtcag caaccatagt cccgcccta actccgcca 2520

tcccgccct aactccgcc agttccgcc attctccgc ccatggtga ctaatttttt 2580

ttatttatgc agaggccgag gccgcctctg cctctgagct attccagaag tagtgaggag 2640

gcttttttg aggcctagc ttttgcaaaa agtccccgg agcttgata tccattttcg 2700

gatctgatca gcacgtgtg acaattaatc atcgcatag tatatcgga tagtataata 2760

cgacaaggtg aggaactaaa ccatggccaa gttgaccagt gccgttcgg tgctcaccgc 2820

gcgcgacgtc gccggagcgg tcgagttctg gaccgaccgg ctccgggttct ccggggactt 2880

cgtggaggac gacttcgccg gtgtgggtccg ggacgacgtg accctgttca tcagcgcggt 2940

ccaggaccag gtggtgccg acaacaccct ggctgggtg tgggtgcgcg gcctggacga 3000

gctgtacgcc gagggtcgg aggtcgtgtc cacgaacttc cgggacgcct ccgggcccgc 3060

catgaccgag atcggcgagc agcgtgggg ggggagttc gccctgcgcg acccgcccg 3120

caactgcgtg cacttcgtg ccgaggagca ggactgacac gtgctacgag atttcgattc 3180

caccgcgcc ttctatgaaa ggttgggtt cggatcgtt ttccgggacg ccggctggat 3240

gacctccag cggggggatc tcatgctgga gttcttcgcc caccccaact tgtttattgc 3300

agcttataat ggttacaaat aaagcaatag catcacaat ttcacaaata aagcattttt 3360

ttcactgcat tctagtgtg gtttgtcaa actcatcaat gtatcttata atgtctgtat 3420

accgtcgacc tctagctaga gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa 3480

ttgttatccg ctacaaatc cacacaacat acgagccgga agcataaagt gtaaagcctg 3540

gggtgcctaa tgagtgaact aactcacatt aattgcgtt cgtcactgc ccgctttcca 3600

gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg ggagaggcgg 3660

tttgcgtatt gggcgctctt ccgcttctc gctcactgac tcgctgcgct cggctgttcg 3720

gctcggcgca gcggtatcag ctactcaaa ggcggaata cggttatcca cagaatcagg 3780

ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa 3840
ggccgcgttg ctggcgtttt tccatagget ccgccccct gacgagcatc acaaaaatcg 3900
acgtcaagt cagaggtggc gaaacccgac aggactataa agataccagg cgtttcccc 3960
tggaagctcc ctctgctgct ctctgttcc gacctgccc cttaccggat acctgtccgc 4020
cttttccct tcggaagcg tggcgctttc tcaatgctca cgctgtaggt atctcagttc 4080
gggtgtaggtc gtctgctcca agctgggctg tgtgcacgaa cccccgttc agcccgaccg 4140
ctgcgcctta tccgtaact atcgtcttga gtccaaccg gtaagacagc atttatcgcc 4200
actggcagca gccactggtc acaggattag cagagcgagg tatgtaggcg gtgctacaga 4260
gttcttgaag tgggtggcta actacggcta cactagaagg acagtatttg gtatctgcgc 4320
tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaac 4380
caccgctggt agcgggtggt tttttgtttg caagcagcag attacgcgc gaaaaaagg 4440
atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtga acgaaaactc 4500
acgttaaggg attttggctc tgagattatc aaaaaggatc ttcacctaga tccttttaaa 4560
ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggc ctgacagtta 4620
ccaatgctta atcagtggag cacctatctc agcgatctgt ctatttcgtt catccatagt 4680

tgctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag 4740

tgctgcaatg ataccgagag acccacgctc accggtcca gatttatcag caataaacca 4800

gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc 4860

tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt 4920

tggtgccatt gctacaggca tcgtgggtgc acgctcgtcg tttggatatg cttcattcag 4980

ctccggttcc caacgatcaa ggcgagttac atgatcccc atgttgtgca aaaaagcggc 5040

tagtccttc ggtcctcga tcgtgtcag aagtaagttg gccgcagtgt tatcactcat 5100

ggttatggca gcaactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt 5160

gactggtgag tactcaacca agtcattctg agaatagttg atgcggcgac cgagttgctc 5220

ttgccccgag tcaatacggg ataataccgc gccacatagc agaactttaa aagtgtcat 5280

cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag 5340

ttcgatgtaa ccaactcgtg caccacaactg atcttcagca tcttttactt tcaccagcgt 5400

ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg 5460

gaaatgttga atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta 5520

ttgtctcatg agcggataca tatttgaatg tatttagaaa aataaacaata taggggttcc 5580

gcgcacattt ccccgaaaag tgccacctga cgtc

5614

<210> 8

<211> 5614

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

pSecTagA-VEGF-B167-H6-NXT

<400> 8

gacggatcgg gagatctccc gatccctat ggtcgactct cagtacaatc tgctctgatg 60

ccgcatagtt aagccagtat ctgctccctg cttgtgtggt ggaggtcgct gagtagtgcg 120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300

tggagtccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360

cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540

atgccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600

tcgctattac catggtgatg cgggttttggc agtacatcaa tgggcgtgga tagcggtttg 660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc ccattgacg caaatgggcg 780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840

ctgcttactg gcttatcgaa attaatacga ctactatag ggagacccaa gctggctagt 900

ccagtgtggt ggaattcggc ttcacatga gccctctgct ccgccgctg ctgctcgccg 960

cactcctgca gctggccccc gccaggccc ctgtctccca gcctgatgcc cctggccacc 1020

agaggaaagt ggtgtcatgg atagatgtgt atactcgcgc tacctgccag ccccgaggag 1080

tggtggtgcc cttgactgtg gagctcatgg gcaccgtggc caaacagctg gtgccagct 1140

gcgtgactgt gcagcgtgt ggtggctgct gccctgacga tggcctggag tgtgtgcca 1200

ctgggcagca caacgtcacc atgcagatcc tcatgatccg gtacccgagc agtcagctgg 1260

gggagatgtc cctggaagaa cacagccagt gtgaatgcag acctaaaaa aaggacagtg 1320

ctgtgaagcc agacagcccc aggccctct gccacgctg caccagcac caccagcgcc 1380

ctgacccccg gacctgccgc tgccgtgcc gacgccgag ctctctccgt tgccaagggc 1440

ggggcttaga gctcaacca gacacctgca ggtgccgga gctgcgaagg catcatcatc 1500
atcatcattg agcggccgct cgagtctaga gggcccgaa aaaaactcat ctcagaagag 1560
gatctgaata gcgcgctga ccatcatcat catcatcatt gagtttaaac ccgctgatca 1620
gcctcgactg tgccttctag ttgccagcca tctgttggtt gccctcccc cgtgccttcc 1680
ttgacctgg aaggtgccac tccactgtc ctttcctaataaaaatgagga aattgcatcg 1740
cattgtctga gtaggtgtca ttctattctg gggggtgggg tggggcagga cagcaagggg 1800
gaggattggg aagacaatag caggcatgct ggggatgagg tgggtcttat ggcttctgag 1860
gcggaaagaa ccagctgggg ctctaggggg tatccccacg cgcctgtag cggcgatta 1920
agcgcgcggg gtgtgggtgt tacgcgcagc gtgaccgcta cacttgccag cgcctagcg 1980
cccgctcctt tcgctttctt cccttcctt ctcgccagc tcgcgggctt tccccgtcaa 2040
gctctaaatc ggggcatccc tttagggttc cgatttagtg ctttacggca cctcgacccc 2100
aaaaaacttg attaggggtga tggttcacgt agtgggcat cgcctgata gacgggtttt 2160
cgcccttga cgttgagtc cacgttctt aatagtgac tctgttcca aactggaaca 2220
acactcaacc ctatctcgtt ctattctttt gatttataag ggattttggg gatttcggcc 2280
tattggttaa aaaatgagct gatttaacaa aaatttaacg cgaattaatt ctgtggaatg 2340

tgtgtcagtt aggggtgtgga aagtccccag gctccccagc aggcagaagt atgcaaagca 2400

tgcattctcaa ttagtcagca accagggtgtg gaaagtcccc aggctcccca gcaggcagaa 2460

gtatgcaaag catgcatctc aattagtcag caaccatagt cccgccccta actccgcccc 2520

tcccgccct aactccgcc agttccgcc attctccgcc ccatggctga ctaatttttt 2580

ttatttatgc agaggccgag gccgcctctg cctctgagct attccagaag tagtgaggag 2640

gcttttttg aggcctaggc ttttgcaaaa agtccccggg agcttgata tccatttttcg 2700

gatctgatca gcacgtgtg acaattaatc atcgcatag tatatcgga tagtataata 2760

cgacaagggtg aggaactaaa ccatggccaa gttgaccagt gccgttccgg tgctcaccgc 2820

gcgcgacgtc gccggagcgg tcgagttctg gaccgaccgg ctccgggttct cccgggactt 2880

cgtggaggac gacttcgccg gtgtgggtccg ggacgacgtg accctgttca tcagcgcggt 2940

ccaggaccag gtggtgccg acaacaccct ggctgggtg tgggtgcgcg gcctggacga 3000

gctgtacgcc gagtggtcgg aggtcgtgtc cacgaacttc cgggacgcct ccgggccggc 3060

catgaccgag atcggcgagc agcctggggg gcgggagttc gccctgcgcg acccgccgg 3120

caactgcgtg cacttcgtgg ccgaggagca ggactgacac gtgctaagag atttcgattc 3180

caccgccgcc ttctatgaaa ggttgggctt cggaatcgtt ttccgggacg ccggctggat 3240

gatcctccag cgcggggatc tcatgctgga gttcttcgcc caccccaact tgttttattgc 3300

agcttataat gggtacaaat aaagcaatag catcacaaat ttcacaaata aagcattttt 3360

ttcaactgcat tctagttgtg gtttgtocaa actcatcaat gtatcttato atgtctgtat 3420

accgtcgacc tctagctaga gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa 3480

ttgttatccg ctcacaattc cacacaacat acgagccgga agcataaagt gtaaagcctg 3540

gggtgcctaa tgagtgaagt aactcacatt aattgcgttg cgctcactgc ccgctttcca 3600

gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg ggagaggcgg 3660

tttgcgtatt gggcgctctt ccgcttcctc gctcactgac tcgctgcgct cggctcgttcg 3720

gctgcggcga gcggtatcag ctcactcaaa ggcggtaata cggttatcca cagaatcagg 3780

ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa 3840

ggccgcgttg ctggcgtttt tccataggtt ccgccccctt gacgagcatc acaaaaatcg 3900

acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg cgtttccccc 3960

tggaagctcc ctctgcgct ctctgttcc gaccctgccg cttaccggat acctgtccgc 4020

ctttctccct tcgggaagcg tggcgcttcc tcaatgetca cgtgttaggt atctcagttc 4080

ggtgtaggtc gttcgtcca agctgggctg tgtgcacgaa cccccgttc agcccagccg 4140

ctgcgcctta tccggttaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc 4200

actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga 4260
gttcttgaag tgggtggcta actacggcta cactagaagg acagtatttg gtatctgcgc 4320
tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaac 4380
cacgcctggg agcgggtggt tttttgttg caagcagcag attacgcgca gaaaaaagg 4440
atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtga acgaaaactc 4500
acgttaaggg attttggta tgagattatc aaaaaggatc ttcacctaga tccttttaaa 4560
ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggg ctgacagta 4620
ccaatgctta atcagtggg cacctatctc agcgatctgt ctatttcggt catccatagt 4680
tgctgactc ccgctcgtgt agataactac gatacgggag ggcttaccat ctggccccag 4740
tgctgcaatg ataccgcgag acccacgctc accggctcca gatttatcag caataaacca 4800
gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgct ccatccagtc 4860
tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt 4920
tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg cttcattcag 4980
ctccggttcc caacgatcaa ggcgagttac atgatcccc atgttgtgca aaaaagcggg 5040
tagctccttc ggtcctccga tcgttgctcag aagtaagttg gccgcagtgt tatcactcat 5100

ggttatggca gcactgcata attctcttac tgtcatgccca tccgtaagat gcttttctgt 5160

gactgggtgag tactcaacca agtcattctg agaatagtgt atgcggcgac cgagttgctc 5220

ttgcccggcg tcaatacggg ataataccgc gccacatagc agaactttaa aagtgtcat 5280

cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag 5340

ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt 5400

ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg 5460

gaaatgtga atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta 5520

ttgtctcatg agcggataca tatttgaatg tatttagaaa aataa caaaa taggggttcc 5580

gcgcacattt ccccgaaaag tgccacctga cgtc 5614

<210> 9

<211> 5695

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

pSecTagA-VEGF-B186-H6-NXT

<400> 9

gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggtttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatagc cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggetgaccg cccaacgacc 360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480
atcatatgcc aagtagccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgccagta catgacctta tgggactttc ctacttgga gtacatctac gtattagtca 600
tcgtattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccaccca ttgacgtcaa tgggagtttg ttttgcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc ccattgacg caaatggcg 780
gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaacca 840
ctgcttactg gcttatcgaa attaatacga ctactatag ggagaccaa gctggctagt 900
ccagtgtggt ggaattcggc ttcaccatga gccctctgct ccgccgctg ctgctcgccg 960

cactcctgca gctggccccc gccagggccc ctgtctccca gctgatgcc cctggccacc 1020

agaggaaagt ggtgtcatgg atagatgtgt atactcgcgc tacctgccag ccccgaggagg 1080

tggtggtgcc cttgactgtg gagctcatgg gcaccgtggc caaacagctg gtgcccagct 1140

gcgtgactgt gcagcgtgt ggtggctgct gccctgacga tggcctggag tgtgtgcca 1200

ctgggcagca caacgtcacc atgcagatcc tcctgatccg gtaccgagc agtcagctgg 1260

gggagatgtc cctggaagaa cacagccagt gtgaatgcag acctaaaaaa aaggacagtg 1320

ctgtgaagcc agacagggct gccactcccc accaccgtcc ccagccccgt tctgttccgg 1380

gctgggactc tgcccccgga gcacctccc cagctgacat caccatccc actccagccc 1440

cagggccctc tgcccacgt gcaccagca ccaccagcgc cctgaccccc ggacctgccg 1500

ccgccgtgc cgacgccga gcttctccg ttgccaaggc cggggctcat catcatcatc 1560

atcattgaat tctgcagata tccagcacag tggcgccgc tcgagtctag agggcccgaa 1620

caaaaactca tctcagaaga ggatctgaat agcgccgtcg accatcatca tcacatcat 1680

tgagtttaaa cccgtgatc agcctcgact gtgccttcta gttgccagcc atctgttgtt 1740

tggccctccc ccgtgcctc cttgacctg gaaggtgcc ctcccactgt ctttctctaa 1800

taaaatgagg aaattgcac gcattgtctg agtaggtgtc attctattct ggggggtggg 1860

gtggggcagg acagcaaggg ggaggattgg gaagacaata gcaggcatgc tggggatgcg 1920

gtgggctcta tggttctga ggcggaaaga accagctggg gctctagggg gtatccccac 1980

gcgccctgta gcggcgcatc aagcgcgcg ggtgtggtgg ttacgcgcag cgtgaccgct 2040

acacttgcca gcgccctagc gcccgctcct ttcgctttct tcccttcctt tctcgccacg 2100

ttcgccggct tccccgtca agctctaaat cggggcatcc ctttaggggt ccgatttagt 2160

gctttacggc acctcgacc caaaaaactt gattaggggt atgggttcacg tagtgggcca 2220

tgcacctgat agacggtttt tggcccttg acgttgaggt ccacgttctt taatagtgga 2280

ctcttgttcc aaactggaac aacactcaac cctatctcgg tctattcttt tgatttataa 2340

gggattttgg ggatttcggc ctattggtta aaaaatgagc tgatttaaca aaaatttaac 2400

gcgaattaat tctgtggaat gtgtgtcagt tagggtgtgg aaagtcccca ggctccccag 2460

caggcagaag tatgcaaagc atgcatctca attagtcagc aaccaggtgt ggaaagtccc 2520

caggctcccc agcaggcaga agtatgcaa gcacgcatct caattagtca gcaaccatag 2580

tcccgccct aactccgcc atcccgccc taactccgcc cagttccgcc cattctccgc 2640

cccatggctg actaattttt tttatttatg cagaggccga ggccgctct gcctctgagc 2700

tattccagaa gtagtgagga ggcttttttg gaggcctagg cttttgcaaa aagctcccg 2760

gagcttgat atccattttc ggatctgatc agcacgtgtt gacaattaat catcggcata 2820

gtatatcggc atagtataat acgacaaggt gaggaactaa accatggcca agttgaccag 2880

tgccgttccg gtgtccaccg cgcgcgacgt cgccggagcg gtcgagttct ggaccgaccg 2940

gctcgggttc tcccgggact tcgtggagga cgacttcgcc ggtgtggtcc gggacgacgt 3000

gaccctgttc atcagcgcgg tccaggacca ggtggtgccg gacaacaccc tggcctgggt 3060

gtgggtgcgc ggcctggacg agctgtacgc cgagtggtcg gaggtcgtgt ccacgaactt 3120

ccgggacgcc tccgggccgg ccatgaccga gatcggcgag cagccgtggg ggcgggagtt 3180

cgccctgcgc gacccggccg gcaactgcgt gcaattcgtg gccgaggagc aggactgaca 3240

cgtgctacga gatttcgatt ccaccgccgc cttctatgaa aggttgggct tcggaatcgt 3300

tttcggggac gccggctgga tgatcctcca gcgcggggat ctcatgctgg agttcttcgc 3360

ccacccaac ttgtttattg cagcttataa tggttacaaa taaagcaata gcatcacaaa 3420

tttcacaaat aaagcatttt ttactgca ttctagttgt ggtttgtcca aactcatcaa 3480

tgtatcttat catgtctgta taccgtgcac ctctagctag agcttgccgt aatcatggtc 3540

atagctgttt cctgtgtgaa attgttatcc gtcacaatt ccacacaaca tacgagccgg 3600

aagcataaag tgtaaagcct ggggtgccta atgagtgagc taactcacat taattgcgtt 3660

gcgtcactg cccgctttcc agtcgggaaa cctgtcgtgc cagctgcatt aatgaatcgg 3720

ccaacgcgcg gggagaggcg gtttgcgtat tgggcgctct tccgcttccg cgctcactga 3780

ctcgcctgcgc tcggctcgttc ggctgcggcg agcgggtatca gctcactcaa aggcggtaat 3840

acggttatcc acagaatcag gggataacgc aggaagaac atgtgagcaa aaggccagca 3900

aaaggccagg aaccgtaaaa aggccgcgtt gctggcggtt ttccatagga tccgcccccc 3960

tgacgagcat cacaaaaatc gacgctcaag tcagagggtg cgaaaccga caggactata 4020

aagataccag gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc 4080

gcttaccgga tacctgtccg cctttctccc ttccggaagc gtggcgcttt ctcaatgctc 4140

acgctgtagg tatctcagtt cgggtgtagt cgctcgtcc aagctgggct gtgtgcacga 4200

acccccggt cagcccgacc gctgcgcctt atccggtaac tatcgtcttg agtccaaccc 4260

ggtaagacac gacttatcgc cactggcagc agccactggt aacaggatta gcagagcgag 4320

gatatgtaggc ggtgctacag agttcttgaa gtggtggcct aactacggct acactagaag 4380

gacagtatctt ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa gagttggtag 4440

ctcttgatcc ggcaaacaaa ccaccgctgg tagcggtggt ttttttggtt gcaagcagca 4500

gattacgcgc agaaaaaag gatctcaaga agatcctttg atcttttcta cggggtctga 4560

cgctcagtgg aacgaaaact cacgttaagg gattttggtc atgagattat caaaaaggat 4620

cttcacctag atccttttaa attaaaaatg aagtttttaa tcaatctaaa gtatatatga 4680

gtaaaacttg tctgacagtt accaatgctt aatcagtgag gcacctatct cagcgatctg 4740

tctatttcgt tcatccatag ttgcctgact ccccgctctg tagataacta cgatacggga 4800

gggcttacca tctggcccca gtgctgcaat gataccgca gacccacgct caccggctcc 4860

agatttatca gcaataaacc agccagccgg aagggccgag cgcagaagtg gtcctgcaac 4920

tttatccgcc tocatccagt ctattaattg ttgccgggaa gctagagtaa gtagttcgcc 4980

agttaatagt ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt cagcctcgtc 5040

gtttggtatg gcttcattca gctccggttc ccaacgatca aggcgagtta catgatcccc 5100

catgttgtgc aaaaaagcgg ttagctcctt cggtcctccg atcgttgtca gaagtaagtt 5160

ggccgcagtg ttatcactca tggttatggc agcactgcat aattctctta ctgtcatgcc 5220

atccgtaaga tgcttttctg tgactggtga gtactcaacc aagtcattct gagaatagtg 5280

tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataataccg cgccacatag 5340

cagaacttta aaagtgtca tcattggaaa acgttcttcg gggcgaaaac tctcaaggat 5400

cttaccgctg ttgagatcca gttcgatgta acccactcgt gcaccaact gatcttcagc 5460

atcttttact ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa atgccgcaaa 5520

aaaggggaata agggcgacac ggaaatgttg aatactcata ctcttccttt ttcaatatta 5580

ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat gtatttagaa 5640

aaataaaca ataggggttc cgcgcacatt tccccgaaaa gtgccacctg acgtc) 5695

<210> 10

<211> 5695

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

pSecTagA-VEGF-B186-H6

<400> 10

gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240

gattattgac tagttattaa tagtaatcaa ttacgggggc attagttcat agcccatata 300

tggagtccg cgttacataa cttacggtaa atggcccgcc tggetgaccg cccaacgacc 360

cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420

attgacgtca atgggtggac tatttacggt aaactgcca cttggcagta catcaagtgt 480

atcatatgcc aagtacgcc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540

atgcccagta catgacctta tgggactttc ctacttgga gtacatctac gtattagtca 600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc ccattgacg caaatgggag 780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaacca 840

ctgcttactg gcttatcgaa attaatacga ctcaactatag ggagacccaa gctggctagt 900

ccagtgtggt ggaattcggc ttcacatga gccctctgct ccgccgctg ctgctcgccg 960

cactcctgca gctggccccc gccaggccc ctgtctccca gcctgatgcc cctggccacc 1020

agaggaaagt ggtgtcatgg atagatgtgt atactcggc tacctgccag ccccgaggag 1080

tggtggtgcc cttgactgtg gagctcatgg gcaccgtggc caaacagctg gtgccagct 1140

gcgtgactgt gcagcgtgt ggtggctgct gccctgacga tggcctggag tgtgtgcca 1200

ctgggcagca ccaagtccg atgcagatcc tcatgatccg gtacccgagc agtcagctgg 1260

gggagatgtc cctggaagaa cacagccagt gtgaatgcag acctaaaaa aaggacagt 1320

ctgtgaagcc agacagggct gccactcccc accaccgtcc ccagccccgt tctgttccgg 1380

gctgggactc tgcccccgga gcacctccc cagctgacat caccatccc actccagccc 1440

caggccccctc tgcccacgct gcaccacgca ccaccagcgc cctgaccccc ggacctgccg 1500

ccgccgctgc cgacgccgca gcttctccg ttgccaaagg cggggctcat catcatcatc 1560

atcattgaat tctgcagata tccagcacag tggcgccgc tcgagtctag agggcccgaa 1620

caaaaactca tctcagaaga ggatctgaat agcgccgtcg accatcatca tcatcatcat 1680

tgagtttaaa cccgtgatc agcctcgact gtgccttcta gttgccagcc atctgttggt 1740

tgccccctccc ccgtgccttc cttgaccctg gaaggcgcca ctcccactgt cctttcctaa 1800

taaaatgagg aaattgcac gcattgtctg agtaggtgtc attctattct ggggggtggg 1860

gtggggcagg acagcaaggg ggaggattgg gaagacaata gcaggcatgc tggggatgcg 1920

gtgggctcta tggcttctga ggcggaaaga accagctggg gctctagggg gtatccccac 1980

gcgccctgta gcggcgcat aagcgcgcg ggtgtggtg ttacgcgcag cgtgaccgct 2040

acatttgcca gcgccctagc gcccgctcct ttcgctttct tcccttcctt tctcgccacg 2100

ttcgccggct ttccccgtca agctctaaat cggggcatcc ctttaggggt ccgatttagt 2160

gctttacggc acctcgaccc caaaaaactt gattaggggt atggttcacg tagtgggcca 2220

tcgccctgat agacgggttt tcgccctttg acgttgaggt ccacgttctt taatagtgga 2280

ctcttgttcc aaactggaac aacactcaac cctatctcgg tctattcttt tgatttataa 2340
gggattttgg ggatttcggc ctattgggta aaaaatgagc tgatttaaca aaaatttaac 2400
gcgaattaat tctgtggaat gtgtgtcagt taggggtgtg aaagtcccca ggctccccag 2460
caggcagaag tatgcaaagc atgcatctca attagtcagc aaccaggtgt ggaaagtccc 2520
caggctcccc agcaggcaga agtatgcaaa gcatgcatct caattagtca gcaaccatag 2580
tcccgcacct aactccgcc atcccgcctc taactccgcc cagttccgcc cattctccgc 2640
cccatggctg actaattttt tttatttatg cagaggccga ggccgcctct gcctctgagc 2700
tattccagaa gtagtgagga ggcttttttg gaggcctagg 'cttttgcaaa aagctcccgg 2760
gagcttgat atccattttc ggatctgatc agcacgtgtt gacaattaat catcggcata 2820
gtatatcggc atagtataat acgacaaggt gaggaactaa accatggcca agttgaccag 2880
tgccgttccg gtgctcaccg cgcgcgacgt cgccggagcg gtcgagttct ggaccgaccg 2940
gtcggggttc tcccgggact tcgtggagga cgacttcgcc ggtgtggtcc gggacgacgt 3000
gaccctgttc atcagcgcgg tccaggacca ggtggtgccg gacaacaccc tggcctgggt 3060
gtgggtgctc ggctggacg agctgtacgc cgagtggctg gaggtcgtgt ccacgaactt 3120
ccgggacgcc tccggggccg ccatgaccga gatcggcgag cagccgtggg ggcgggagtt 3180

cgccctgcgc gaccgcggcgc gcaactgcgt gcacttcgtg gccgaggagc aggactgaca 3240

cgtgctacga gatttcgatt ccaccgcgc cttctatgaa aggttgggct tcggaatcgt 3300

tttcggggac gccggctgga tgatcctcca gcgcggggat ctcctgctgg agttcttcgc 3360

ccaccccaac ttgtttattg cagcttataa tggttacaaa taaagcaata gcatcacaaa 3420

tttcacaaat aaagcatttt tttcactgca ttctagttgt ggtttgcca aactcatcaa 3480

tgtatcttat catgtctgta taccgtcgac ctctagctag agcttgccgt aatcatggtc 3540

atagctgttt cctgtgtgaa attgttatcc gctcacaatt ccacacaaca tacgagccgg 3600

aagcataaag tgtaaagcct ggggtgccta atgagtgagc taactcacat taattgcgtt 3660

gcgctcactg cccgctttcc agtcgggaaa cctgtcgtgc cagctgcatt aatgaatcgg 3720

ccaacgcgcg gggagaggcg gtttgcgtat tgggcgtct tccgcttcct cgctcactga 3780

ctcgtgcgc tcggtcgttc ggctgcggcg agcggatatca gctcactcaa aggcggtaat 3840

acggttatcc acagaatcag gggataacgc aggaagaac atgtgagcaa aaggccagca 3900

aaaggccagg aaccgtaaaa aggcgcggtt gctggcggtt ttccataggc tccgcccccc 3960

tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg cgaaaccgca caggactata 4020

aagataccag gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc 4080

gcttaccgga tacctgtccg cctttctccc ttccggaagc gtggcgcttt ctcaatgctc 4140

acgtgtagg tatctcagtt cgggtgtaggt cgctcgctcc aagctgggct gtgtgcacga 4200

acccccggt cagcccgacc gctgcgcctt atccggtaac tatcgtcttg agtccaaccc 4260

ggtaagacac gacttatcgc cactggcagc agccactggc aacaggatta gcagagcgag 4320

gtatgtaggc ggtgctacag agttcttgaa gtgggtggcct aactacggct acactagaag 4380

gacagtatctt ggtatctgcg ctctgctgaa gccagttacc ttccgaaaaa gaggtaggtg 4440

ctcttgatcc ggcaaaaaa ccaccgctgg tagcgggtgg ttttttggtt gcaagcagca 4500

gattacgctc agaaaaaag gatctcaaga agatcctttg atcttttcta cgggggtctga 4560

cgctcagtg aacgaaaact cacgttaagg gattttggct atgagattat caaaaaggat 4620

cttcacctag atccttttaa attaaaaatg aagtttttaa tcaatctaaa gtatatatga 4680

gtaaaacttg tctgacagtt accaatgctt aatcagtgag gcacctatct cagcgatctg 4740

tctatttcgt tcatccatag ttgcctgact ccccgctgtg tagataacta cgatacggga 4800

gggcttacca tctggcccca gtgctgcaat gataccgcga gacccacgct caccggctcc 4860

agatttatca gcaataaacc agccagccgg aagggccgag cgcagaagtg gtctgcaac 4920

tttatccgcc tccatccagt ctattaattg ttgccgggaa gctagagtaa gtagttcgcc 4980

agttaatagt ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt cacgctcgtc 5040

gtttggtatg gcttcattca gctccggttc ccaacgatca aggcgagtta catgatcccc 5100

catgttgtgc aaaaaagcgg ttagctcctt cggctctccg atcgttgta gaagtaagtt 5160

ggcgcagtg ttatcactca tggttatggc agcactgcat aattctctta ctgtcatgcc 5220

atccgtaaga tgcttttctg tgactgggta gtactcaacc aagtcattct gagaatagtg 5280

tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataataccg cgccacatag 5340

cagaacttta aaagtgtca tcattggaaa acgttcttcg gggcgaaaac tctcaaggat 5400

cttaccgctg ttgagatcca gttcgatgta acccactcgt gcaccaact gatcttcagc 5460

atcttttact ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa atgccgcaaa 5520

aaagggata agggcgacac ggaaatgttg aatactcata ctcttccttt ttcaatatta 5580

ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat gtatttagaa 5640

aaataaaca ataggggttc cgcgcacatt tccccgaaaa gtgccacctg acgtc 5695

<210> 11

<211> 5458

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

pSecTagA-VEGF-BEx1-5-H6

<400> 11

gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60

ccgcatagtt aagccagtat ctgctccctg cttgtgtggt ggaggtcgct gagtagtgcg 120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360

cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420

attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540

atgcccagta catgacctta tgggactttc ctacttgga gtacatctac gtattagtca 600

tcgtattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660

actcacgggg atttccaagt ctccaccca ttgacgtcaa tgggagtgtg ttttggcacc 720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc ccattgacg caaatgggcg 780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840

ctgcttactg gcttatcgaa attaatagca ctactatag ggagacccaa gctggctagt 900

ccagtgtggt ggaattcggc ttcacatga gccctctgct ccgccgctg ctgctcgccg 960

cactcctgca gctggccccc gccagggccc ctgtctccca gcctgatgcc cctggccacc 1020

agaggaaagt ggtgtcatgg atagatgtgt atactcgcg tacctgccag ccccgaggag 1080

tgggtgtgcc cttgactgtg gagctcatgg gcaccgtggc caaacagctg gtgccagct 1140

gcgtgactgt gcagcgtgt ggtggtgct gccctgacga tggcctggag tgtgtgcca 1200

ctgggcagca ccaagtcgg atgcagatcc tcctgatccg gtacccgagc agtcagctgg 1260

gggagatgtc cctggaagaa cacagccagt gtgaatgcag acctaaaaa aaggacagt 1320

ctgtgaagcc agaccatcat catcatcacc actgagcggc cgctcgagtc tagaggcccc 1380

gaacaaaaac tcctctcaga agaggatctg aatagcgccg tcgaccatca tcctcatcat 1440

cattgagttt aaaccgctg atcagcctcg actgtgcctt ctagtgtcca gccatctgtt 1500

gtttgccct ccccgctgc ttccttgacc ctggaagtg ccactccac tgcctttcc 1560

taataaaatg aggaaattgc atcgattgt ctgagtaggt gtcattctat tctggggggt 1620

ggggtggggc aggacagcaa gggggaggat tgggaagaca atagcaggca tgctggggat 1680

gcggtgggct ctatggcttc tgaggcgga agaaccagct ggggctctag ggggtatccc 1740

cacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg cagcgtgacc 1800

gctacadtgg ccagcgccct agcgcccgt ctttcgctt tttcccttc cttctcgcc 1860

acgttcgccc gctttccccc tcaagctcta aatcggggca tccctttagg gttccgattt 1920

agtgccttac ggcacctcga ccccaaaaaa cttgattagg gtgatggttc acgtagtggg 1980

ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt ctttaatagt 2040

ggactcttgt tccaaactgg aacaacactc aaccctatct cggctattc ttttgattta 2100

taagggattt tggggatttc ggcctattgg ttaaaaaatg agctgattta acaaaaattt 2160

aacgcgaatt aattctgtgg aatgtgtgtc agttagggtg tggaaagtcc ccaggctccc 2220

cagcaggcag aagtatgcaa agcatgcac tcaattagtc agcaaccagg tgtggaaagt 2280

cccaggctc ccagcaggc agaagtatgc aaagcatgca tctcaattag tcagcaacca 2340

tagtcccgcc cctaactccg cccatcccg ccctaactcc gccagttcc gccattctc 2400

cgcccatgg ctgactaatt ttttttattt atgcagaggc cgaggccgcc tctgcctctg 2460

agctattcca gaagtagtga ggaggctttt ttggaggcct aggcttttgc aaaaagctcc 2520

cgggagcttg tatatccatt ttcggatctg atcagcacgt gttgacaatt aatcatcggc 2580

atagtatac ggcatagtat aatacgacaa ggtgaggaac taaacctagg ccaagttgac 2640

cagtgcggtt ccggtgctca ccgcgcgcga cgtcgccgga gcggtcgagt tctggaccga 2700

ccggctcggg ttctcccgga acttcgtgga ggacgacttc gccggtgtgg tccgggacga 2760

cgtgaccctg ttcattcagcg cgggtccagga ccaggtggtg ccggacaaca ccctggcctg 2820

ggtgtgggtg cgcggcctgg acgagctgta cgcgagtggtg tcggaggtcg tgtccacgaa 2880

cttcggggac gcctccgggc cggccatgac cgagatcggc gagcagccgt gggggcgagg 2940

gttcgccttg cgcgaccgga ccggcaactg cgtgcacttc gtggccgagg agcaggactg 3000

acacgtgcta cgagatttcg attccaccgc cgccttctat gaaagggttg gcttcggaat 3060

cgttttccgg gacgcgggct ggatgacctt ccagcgcgga gatctcatgc tggagttctt 3120

cgcccccccc aacttggtta ttgcagctta taatggttac aaataaagca atagcatcac 3180

aaatttcaca aataaagcat ttttttcaact gcattctagt tgtggtttgt ccaaactcat 3240

caatgtatct tatcatgtct gtataccgct gacctctagc tagagcttgg cgtaatcatg 3300

gtcatagctg tttcctgtgt gaaattgtta tccgctcaca attccacaca acatacagac 3360

cggaagcata aagtgtaaaag cctgggggtgc ctaatgagtg agctaactca cattaattgc 3420

gttgcgctca ctgccgctt tccagtcggg aaacctgtcg tgccagctgc attaatgaat 3480

cggccaaacgc gcggggagag gcggtttgctg tattgggcgc tcttcgctt cctcgctcac 3540

tgactcgctg cgctcggtcg ttccggctgcg gcgagcggta tcagctcact caaaggcggc 3600

aatacgggta tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca 3660

gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc 3720

ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact 3780

ataaagatac caggcggttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct 3840

gcgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcaatg 3900

ctcacgctgt aggtatctca gtccgggtga ggtcgttcgc tccaagctgg gctgtgtgca 3960

cgaaccccc gttcagcccc accgctgcgc cttatccggt aactatcgtc ttgagtccaa 4020

cccggtaaga cagcacttat cgccactggc agcagccact ggtaacagga ttagcagagc 4080

gaggtatgta ggcggtgcta cagagttctt gaagtgttg cctaactacg gctacactag 4140

aaggacagta tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg 4200

tagctcttga tccggcaaac aaaccaccgc tggtagcggg gggttttttg tttgcaagca 4260

gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacgggggc 4320

tgacgctcag tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag 4380

gatcttcacc tagatccttt taaattaaat atgaagtttt aaatcaatct aaagtatata 4440

tgagtaaact tggctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat 4500

ctgtctatatt cgttcatcca tagttgcctg actccccgtc gtgtagataa ctacgatacg 4560

ggagggctta ccattctggcc ccagtgtgc aatgataccg cgagaccac gctcaccggc 4620

tccagattta tcagcaataa accagccagc cggaagggcc gagcgagaa gtggctctgc 4680

aactttatcc gctccatcc agtctattaa ttgttgccg gaagctagag taagtagttc 4740

gccagttaat agtttgcca acgttggtgc cattgctaca ggcacgtgg tgcacgctc 4800

gtcgtttggt atggcttcat tcagctccg ttcccaacga tcaaggcgag ttacatgatc 4860

ccccatgttg tgcaaaaaag cggtagctc ctccggtcct ccgacgttg tcagaagtaa 4920

gttgccgca gtgttatcac tcattggtat ggcagcactg cataattctc ttactgtcat 4980

gccatccgta agatgctttt ctgtgactgg tgagtactca accaagtcac tctgagaata 5040

gtgtatgcgg cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca 5100

tagcagaact ttaaaagtgc tcattcattgg aaaacgttct tcggggcgaa aactctcaag 5160

gatcttaccg ctgttgagat ccagttcgat gtaaccact cgtgcacca actgatcttc 5220

agcatctttt actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc 5280

aaaaaaggga ataaggcgca cacggaaatg ttgaatactc atactcttcc tttttcaata 5340

ttattgaagc atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta 5400

gaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgccac ctgacgtc 5458

<210> 12

<211> 5458

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

pSecTagA-VEGF-BEx1-5-H6-NXT

<400> 12

gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60

ccgcatagtt aagccagtat ctgctccctg cttgtgtggt ggaggtcgct gagtagtgcg 120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatagc cgttgacatt 240

gattattgac tagttattaa tagtaatcaa ttacgggggc attagttcat agcccatata 300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360

cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420

attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480

atcatatgcc aagtagcgcc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540

atgccagta catgacctta tgggactttc ctacttgga gtacatctac gtattagtca 600

tcgtattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660

actcacgggg atttccaagt ctccaccca ttgacgtcaa tgggagtttg ttttggcacc 720

aaaatcaacg ggactttcca aaatgtcgta acaactcgc cccattgacg caaatgggcg 780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaacca 840

ctgcttactg gcttatcgaa attaatacga ctactatag ggagacccaa gctggctagt 900

ccagtgtggt ggaattcggc ttcacatga gccctctgct ccgcgcctg ctgctcgccg 960

cactcctgca gctggccccc gccaggccc ctgtctcca gcctgatgcc cctggccacc 1020

agaggaaagt ggtgtcatgg atagatgtgt atactcgcg tacctgccag cccggggagg 1080

tggtggtgcc cttgactgtg gagtcatgg gcaccgtggc caaacagctg gtgcccagct 1140

gcgtgactgt gcagcgtgt ggtggctgct gccctgacga tggcctggag tgtgtgcca 1200

ctgggcagca caacgtcacc atgcagatcc tcatgatccg gtacccgagc agtcagctgg 1260

gggagatgtc cctggaagaa cacagccagt gtgaatgcag acctaaaaaa aaggacagt 1320

ctgtgaagcc agaccatcat catcatcacc actgagcggc cgctcgagtc tagagggccc 1380

gaacaaaaac tcatctcaga agaggatctg aatagcgccg tcgaccatca tcatcatcat 1440

cattgagttt aaaccegetg atcagcctcg actgtgcctt ctagttgccca gccatctgtt 1500

gtttgccct ccccggtgcc ttcttgacc ctggaagggtg ccactccac tgtcctttcc 1560

taataaaatg aggaaattgc atcgattgt ctgagtaggt gtcattctat tctggggggt 1620

ggggtggggc aggacagcaa gggggaggat tgggaagaca atagcaggca tgctggggat 1680

gcggtgggct ctatggcttc tgaggcgga agaaccagct ggggctctag ggggtatccc 1740

cacgcgcct gtagcggcg attaagcgcg gcgggtgtgg tggttacgcg cagcgtgacc 1800

gctacacttg ccagcgccct agcgccgct cctttcgctt tcttcccttc cttctcgcc 1860

acgttcgctg gctttcccg tcaagctcta aatcggggca tcccttagg gttccgattt 1920

agtgccttac ggcacctga ccccaaaaaa cttgattagg gtgatggttc acgtagtggg 1980

ccatgcctt gatagacggt ttttcgccc ttgacgttg agtccacgtt ctttaatagt 2040

ggactcttgt tccaaactgg aacaacactc aacctatct cggctctatc ttttgattta 2100

taagggtttt tggggatttc ggcctattgg ttaaaaaatg agctgattta acaaaaattt 2160

aacgcgaatt aattctgtgg aatgtgtgtc agttagggtg tggaaagtcc ccaggctccc 2220

cagcaggcag aagtatgcaa agcatgcatc tcaattagtc agcaaccagg tgtggaaagt 2280

ccccaggctc ccagcaggc agaagtatgc aaagcatgca tctcaattag tcagcaacca 2340

tagtcccgcc cctaactccg cccatcccg ccctaactcc gccagttcc gccattctc 2400

cgcccatgg ctgactaatt tttttatatt atgcagaggg cgaggccgcc tctgcctctg 2460

agctattcca gaagtagtga ggaggctttt ttggaggcct aggcttttgc aaaaagctcc 2520

egggagcttg tataatccatt ttggatctg atcagcacgt gttgacaatt aatcatcgcc 2580

atagtatatc ggcatagtat aatacgacaa ggtgaggaac taaaccatgg ccaagttgac 2640

cagtgccgtt ccggtgctca ccgcgcgcga cgtcgccgga gcggtcgagt tctggaccga 2700

ccggctcggg ttctcccgga acttcgtgga ggacgacttc gccggtgtgg tccgggacga 2760

cgtgaccctg ttcacacgg cggtccagga ccagggtgtg ccggacaaca ccctggcctg 2820

ggtgtgggtg ccgggcctgg acgagctgta cgcgagtggt tcggaggtcg tgtccacgaa 2880

cttcggggac gcctccgggc cggccatgac cgagatcgcc gagcagccgt gggggcggga 2940

gttcgccctg cgcgaccgg ccggcaactg cgtgcacttc gtggccgagg agcaggactg 3000

acacgtgcta cgagatttcg attccaccgc cgccttctat gaaaggttg gcttcggaat 3060

cgttttccgg gacgccggtt ggatgacct ccagcgcggt gatctcatgc tggagttctt 3120

cgccacccc aacttgttta ttgcagctta taatggttac aaataaagca atagcatcac 3180

aaatttcaca aataaagcat ttttttcaact gcattctagt tgtggtttgt ccaaactcat 3240

caatgtatct tatcatgtct gtataccgtc gacctctagc tagagcttgg cgtaatcatg 3300

gtcatagctg tttcctgtgt gaaattgtta tccgtcaca attccacaca acatacgagc 3360

cggaagcata aagtgtaaag cctgggggtgc ctaatgagtg agctaactca cattaattgc 3420

gttgcgctca ctgccgctt tccagtcggg aaacctgtcg tgccagctgc attaatgaat 3480

cggccaacgc gcggggagag gcggtttgcg tattgggcgc tcttccgctt cctcgctcac 3540

tgactcgctg cgctcggtcg ttcggtgctg gcgagcggta tcagctcact caaaggcggt 3600

aatacgggta tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca 3660

gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc 3720

ccctgacgag catcacaaaa atcgacgtc aagtcagagg tggcgaaacc cgacaggact 3780

ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgacct 3840

gccgcttacc ggatacctgt cgcctttct cccttcggga agcgtggcgc tttctcaatg 3900

ctcacgctgt aggtatctca gttcgggtgta ggtcgttcgc tccaagctgg gctgtgtgca 3960

cgaaccccc gttcagcccc accgtgcgc cttatccggg aactatcgtc ttgagtccaa 4020

cccggtaaga cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc 4080

gaggtatgta ggcgggtgta cagagttctt gaagtgggtg cctaactacg gctacactag 4140

aaggacagta tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg 4200

tagctcttga tccggcaaac aaaccaccgc tggtagcggg ggtttttttg tttgcaagca 4260

gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacgggggc 4320

tgacgctcag tggaacgaaa actcacgtta agggattttg gtcattgagat tatcaaaaag 4380

gatcttcacc tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata 4440

tgagtaaaact tggcttgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat 4500

ctgtctattt cgttcaccca tagttgctg actccccgtc gtgtagataa ctacgatagc 4560

ggagggctta ccattctggcc ccagtgtctg aatgataccg cgagaccac gctcacgggc 4620

tccagattta tcagcaataa accagccagc cggaagggcc gagcgcagaa gtggtcctgc 4680

aaatttatcc gctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc 4740

gccagttaat agtttgcca acgttggtgc cattgctaca ggcacgtgg tgtcacgctc 4800

gtcgtttggt atggcttcat tcagctccgg ttcccaacga tcaaggcgag ttacatgac 4860

ccccatgttg tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg tcagaagtaa 4920

gttgccgca gtgttatcac tcatggttat ggcagcactg cataattctc ttactgtcat 4980

gccatccgta agatgctttt ctgtgactgg tgagtactca accaagtcac tctgagaata 5040

gtgtatgcgg cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca 5100

tagcagaact ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa aactctcaag 5160

gatcttaccg ctgttgagat ccagttcgat gtaaccact cgtgcaccca actgatcttc 5220

agcatctttt actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc 5280

aaaaaagga ataagggcga cacggaaatg ttgaatactc atactcttcc tttttcaata 5340

ttattgaagc atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta 5400

gaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgccac ctgacgtc 5458

<210> 13

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer to
introduce a N-glycosylation site at positions
289-297 of SEQ ID NO:3 (VEGF-B186)

<400> 13

tcggtaccgg atcatgagga tctgcatggt gacgttgtgc tgcccagtgg cca 53

<210> 14

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR 5' primer
for amplification of nucleotides 250 to 567 from
Genebank Acc. No. U48801

<400> 14

cctgacgatg gctggagtg t

21

<210> 15

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR 3' primer
for amplification of nucleotides 250 to 567 from
Genebank Acc. No. U48801

<400> 15

gagcggccgc tcaatgatga tgatgatgat gccttcgcag cttccggcac

50

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR 5' primer
for amplification of nucleotides 1 to 411 from
Genebank Acc. No. U48801

<400> 16

caccatgagc cctctgctcc

20

<210> 17

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR 3'
primer for amplification of nucleotides 1 to 411
from Genebank Acc. No. U48801

<400> 17

gagcggccgc tcagtgggtga tgatgatggt ctggcttcac agcactg

47